<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65109</article-id><article-id pub-id-type="doi">10.7554/eLife.65109</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Mitochondrial respiration contributes to the interferon gamma response in antigen-presenting cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-216613"><name><surname>Kiritsy</surname><given-names>Michael C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8364-8088</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257401"><name><surname>McCann</surname><given-names>Katelyn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216704"><name><surname>Mott</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68722"><name><surname>Holland</surname><given-names>Steven M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-171932"><name><surname>Behar</surname><given-names>Samuel M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3374-6699</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-2049"><name><surname>Sassetti</surname><given-names>Christopher M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6178-4329</contrib-id><email>christopher.sassetti@umassmed.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-140020"><name><surname>Olive</surname><given-names>Andrew J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3441-3113</contrib-id><email>oliveand@msu.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Microbiology and Physiological Systems, University of Massachusetts Medical School</institution><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Immunopathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Microbiology &amp; Molecular Genetics, College of Osteopathic Medicine, Michigan State University</institution><addr-line><named-content content-type="city">East Lansing</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Horng</surname><given-names>Tiffany</given-names></name><role>Reviewing Editor</role><aff><institution>Shanghai Tech University</institution><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Garrett</surname><given-names>Wendy S</given-names></name><role>Senior Editor</role><aff><institution>Harvard T.H. Chan School of Public Health</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e65109</elocation-id><history><date date-type="received" iso-8601-date="2020-11-23"><day>23</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-10-28"><day>28</day><month>10</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2020-11-23"><day>23</day><month>11</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.11.22.393538"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-65109-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-65109-figures-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="article-reference" xlink:href="10.7554/eLife.65110"/><abstract><p>The immunological synapse allows antigen-presenting cells (APCs) to convey a wide array of functionally distinct signals to T cells, which ultimately shape the immune response. The relative effect of stimulatory and inhibitory signals is influenced by the activation state of the APC, which is determined by an interplay between signal transduction and metabolic pathways. While pathways downstream of toll-like receptors rely on glycolytic metabolism for the proper expression of inflammatory mediators, little is known about the metabolic dependencies of other critical signals such as interferon gamma (IFNγ). Using CRISPR-Cas9, we performed a series of genome-wide knockout screens in murine macrophages to identify the regulators of IFNγ-inducible T cell stimulatory or inhibitory proteins MHCII, CD40, and PD-L1. Our multiscreen approach enabled us to identify novel pathways that preferentially control functionally distinct proteins. Further integration of these screening data implicated complex I of the mitochondrial respiratory chain in the expression of all three markers, and by extension the IFNγ signaling pathway. We report that the IFNγ response requires mitochondrial respiration, and APCs are unable to activate T cells upon genetic or chemical inhibition of complex I. These findings suggest a dichotomous metabolic dependency between IFNγ and toll-like receptor signaling, implicating mitochondrial function as a fulcrum of innate immunity.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>IFN gamma</kwd><kwd>APC function</kwd><kwd>complex I</kwd><kwd>PD-L1 regulation</kwd><kwd>mitochondrial respiration</kwd><kwd>immunometabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI146504</award-id><principal-award-recipient><name><surname>Olive</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI132130</award-id><principal-award-recipient><name><surname>Sassetti</surname><given-names>Christopher M</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH2010147</award-id><principal-award-recipient><name><surname>Olive</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000199</institution-id><institution>U.S. Department of Agriculture</institution></institution-wrap></funding-source><award-id>NIFA HATCH 1019371</award-id><principal-award-recipient><name><surname>Olive</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Complex I of the mitochondrial respiratory chain is necessary for interferon gamma-mediated responses in antigen-presenting cells and is required for CD4+ T cell activation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>During the initiation of an adaptive immune response, the antigen-presenting cell (APC) serves as a point of integration where tissue-derived signals are conveyed to T cells. Myeloid APCs, such as macrophages and dendritic cells (DCs), are responsible for the display of specific peptides in complex with major histocompatibility complex (MHC) molecules, and for the expression of co-signaling factors that tune the T cell response (<xref ref-type="bibr" rid="bib107">Sharpe, 2009</xref>). The expression of stimulatory or inhibitory co-signaling molecules depends on the local immune environment and activation state of the APC (<xref ref-type="bibr" rid="bib4">Attanasio and Wherry, 2016</xref>). In particular, interferon gamma (IFNγ) stimulates the surface expression of MHC proteins (<xref ref-type="bibr" rid="bib117">Ting and Trowsdale, 2002</xref>; <xref ref-type="bibr" rid="bib25">Buxadé et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Herrero et al., 2001</xref>; <xref ref-type="bibr" rid="bib100">Reith et al., 2005</xref>; <xref ref-type="bibr" rid="bib101">Rock et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Steimle et al., 1994</xref>; <xref ref-type="bibr" rid="bib127">Wheelock, 1965</xref>), co-stimulatory proteins such as CD40, and the secretion of cytokines like IL-12 and IL-18 (<xref ref-type="bibr" rid="bib118">Tominaga et al., 2000</xref>), to promote T cell activation and the production of IFNγ-producing T-helper type 1 (Th1) effector cells (<xref ref-type="bibr" rid="bib92">O’Shea and Paul, 2002</xref>; <xref ref-type="bibr" rid="bib104">Schneider et al., 2010</xref>; <xref ref-type="bibr" rid="bib119">Trinchieri, 2003</xref>; <xref ref-type="bibr" rid="bib61">Johnson-Léger et al., 1997</xref>; <xref ref-type="bibr" rid="bib3">Alderson et al., 1993</xref>). In the context of local inflammation, pattern recognition receptor (PRR) ligands and endogenous immune activators can collaborate with IFNγ to induce the expression of co-inhibitory molecules, like programmed death-ligand 1 (PD-L1) (<xref ref-type="bibr" rid="bib130">Yamazaki et al., 2002</xref>; <xref ref-type="bibr" rid="bib56">Hu and Ivashkiv, 2009</xref>; <xref ref-type="bibr" rid="bib69">Krawczyk et al., 2010</xref>; <xref ref-type="bibr" rid="bib77">Liu et al., 2017</xref>; <xref ref-type="bibr" rid="bib82">McAdam, 1998</xref>; <xref ref-type="bibr" rid="bib90">Nau et al., 2002</xref>; <xref ref-type="bibr" rid="bib103">Schnare et al., 2001</xref>), which binds T cell programmed death receptor 1 (PD1) to limit immune activation and mitigate T cell-mediated tissue damage (<xref ref-type="bibr" rid="bib43">Francisco et al., 2010</xref>; <xref ref-type="bibr" rid="bib1">Abbas and Sharpe, 2005</xref>; <xref ref-type="bibr" rid="bib20">Brown et al., 2003</xref>; <xref ref-type="bibr" rid="bib102">Schildberg et al., 2016</xref>).</p><p>IFNγ mediates these complex effects via binding to a heterodimeric surface receptor (<xref ref-type="bibr" rid="bib16">Bousoik and Montazeri Aliabadi, 2018</xref>; <xref ref-type="bibr" rid="bib46">Garcia-Diaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib36">Ealick et al., 1991</xref>; <xref ref-type="bibr" rid="bib96">Pestka et al., 2004</xref>). The subunits of the complex, IFNGR1 and IFNGR2, assemble once IFNGR1 is bound by its ligand (<xref ref-type="bibr" rid="bib13">Blouin and Lamaze, 2013</xref>; <xref ref-type="bibr" rid="bib71">Lasfar et al., 2014</xref>). Complex assembly promotes the phosphorylation of Janus kinases 1 and 2 (JAK1 and JAK2) followed by activation of the signal transducer and activation of transcription 1 (STAT1) (<xref ref-type="bibr" rid="bib83">Meraz et al., 1996</xref>). Phosphorylated STAT1 then dimerizes and translocates to the nucleus to activate the transcription of genes containing promoters with IFNγ-activated sequences (GAS), which includes other transcription factors such as interferon regulatory factor 1 (<italic>Irf1</italic>) that amplify the expression of a large regulon that includes T cell co-signaling molecules (<xref ref-type="bibr" rid="bib105">Schroder et al., 2004</xref>; <xref ref-type="bibr" rid="bib74">Lehtonen et al., 1997</xref>). The importance of this signaling pathway is evident in a variety of diseases including cancer (<xref ref-type="bibr" rid="bib30">Chen et al., 2012</xref>; <xref ref-type="bibr" rid="bib123">Walser et al., 2007</xref>; <xref ref-type="bibr" rid="bib79">Lyford-Pike et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Garrido et al., 1997</xref>; <xref ref-type="bibr" rid="bib9">Beatty and Paterson, 2001</xref>), autoimmunity (<xref ref-type="bibr" rid="bib97">Pollard et al., 2013</xref>; <xref ref-type="bibr" rid="bib73">Lees and Cross, 2007</xref>), and infection (<xref ref-type="bibr" rid="bib24">Bustamante et al., 2014</xref>). Individuals with inborn deficiencies in IFNγ signaling, including mutations to the receptor (<xref ref-type="bibr" rid="bib91">Newport et al., 1996</xref>; <xref ref-type="bibr" rid="bib62">Jouanguy et al., 1996</xref>), suffer from a defect in Th1 immunity that results in an immunodeficiency termed Mendelian susceptibility to mycobacterial disease (MSMD) (<xref ref-type="bibr" rid="bib2">Alcaïs et al., 2005</xref>; <xref ref-type="bibr" rid="bib15">Bogunovic et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Filipe-Santos et al., 2006</xref>; <xref ref-type="bibr" rid="bib68">Kong et al., 2013</xref>). Conversely, antagonists of IFNγ-inducible inhibitory molecules, such as PD-L1, are the basis for checkpoint inhibitor therapies that effectively promote T cell-mediated tumor immunity (<xref ref-type="bibr" rid="bib102">Schildberg et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Garcia-Diaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib108">Sharpe, 2017</xref>; <xref ref-type="bibr" rid="bib28">Castro et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">George et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Gong et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Ivashkiv, 2018</xref>; <xref ref-type="bibr" rid="bib80">Mahoney et al., 2019</xref>). While the obligate components of the IFNγ signaling pathway are well known, characterization of additional regulators of this response promises to identify both additional causes of immune dysfunction and new therapeutic targets.</p><p>Recent data suggest that cellular metabolism is an important modulator of the APC-T cell interaction. In particular, microbial stimulation of PRRs on the APC induces glycolytic metabolism and this shift in catabolic activity is essential for cellular activation, migration, and CD4+ and CD8+ T cell activation (<xref ref-type="bibr" rid="bib69">Krawczyk et al., 2010</xref>; <xref ref-type="bibr" rid="bib51">Guak et al., 2018</xref>; <xref ref-type="bibr" rid="bib6">Balic et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Carneiro et al., 2018</xref>; <xref ref-type="bibr" rid="bib38">Everts et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Everts et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Jha et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Liu et al., 2017</xref> <xref ref-type="bibr" rid="bib86">Mills et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Jung et al., 2018</xref>; <xref ref-type="bibr" rid="bib94">Palmieri et al., 2020</xref>; <xref ref-type="bibr" rid="bib125">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib5">Baardman et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Mills et al., 2018</xref>; <xref ref-type="bibr" rid="bib116">Tannahill et al., 2013</xref>). The metabolic state of the T cell is also influenced by the local environment and determines both effector function and long-term differentiation into memory cells (<xref ref-type="bibr" rid="bib121">Veldhoen et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Buck et al., 2015</xref>). IFNγ stimulation has been reported to induce glycolysis, suppress the target of rapamycin complex 1 (mTORC1), and modulate both cellular metabolism and translation in macrophages (<xref ref-type="bibr" rid="bib125">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Su et al., 2015</xref>). However, the effects of different metabolic states on IFNγ-stimulated APC function remain unclear.</p><p>To globally understand the cellular pathways that influence IFNγ-dependent APC function, we used a CRISPR-Cas9 knockout (KO) library (<xref ref-type="bibr" rid="bib35">Doench et al., 2016</xref>) in macrophages to perform three parallel forward-genetic screens for regulators of three IFNγ-inducible co-signaling molecules: MHC class II (MHCII), CD40, and PD-L1. We identified positive and negative regulators that controlled each marker, underscoring the complex regulatory networks that influence the interactions between APCs and T cells. Pooled analysis of the screens uncovered shared regulators that contribute to the global IFNγ response. Prominent among these general regulators was complex I of the respiratory chain. We report that the activity of the IFNγ receptor complex and subsequent transcriptional activation depends on mitochondrial function in both mouse and human myeloid cells. Experimental perturbation of respiration inhibits the capacity of both macrophages and DCs to stimulate T cells, identifying mitochondrial function as a central point where local signals are integrated to determine APC function.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Forward genetic screen identifies regulators of IFNγ-inducible MHCII, CD40, and PD-L1 cell surface expression</title><p>To investigate the diverse regulatory pathways underlying the IFNγ response, we examined the expression of three functionally distinct cell surface markers that are induced by IFNγ. These studies used a J2 virus transformed bone marrow-derived macrophage (BMDM) line that expressed Cas9 (<xref ref-type="bibr" rid="bib67">Kiritsy et al., 2021</xref>). Stimulation of these macrophages with IFNγ for 24 hours resulted in the upregulation of T cell stimulatory molecules, MHCII and CD40, and the inhibitory ligand PD-L1 (<italic>Cd274</italic>), on the cell surface (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). To identify genes that regulate the expression of these markers, Cas9-expressing macrophages were transduced with a lentiviral genome-wide KO library containing four single-guide RNAs (sgRNAs) per protein-coding gene and 1000 non-targeting control (NTC) sgRNAs (<xref ref-type="bibr" rid="bib35">Doench et al., 2016</xref>). The KO library was then stimulated with IFNγ, and fluorescently activated cell sorting (FACS) was used to select mutants with high or low cell surface expression of each individual marker (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). For each of the three surface markers, positive and negative selections were performed in duplicate. The sgRNAs contained in the input library and each sorted population were amplified and sequenced (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Forward genetic screen to identify regulators of the IFNγ response.</title><p>(<bold>A</bold>) Representative histograms of the three selected cell surface markers targeted in macrophage CRISPR screens: MHCII, CD40, and PD-L1. Blue histograms indicate expression of each marker in unstimulated macrophages, and alternatively colored histograms show expression following 24 hr stimulation with recombinant murine IFNγ (10 ng/mL). Gates used for sorting ‘high’ and ‘low’ populations are shown. (<bold>B</bold>) Schematic of CRISPR screens. (<bold>C</bold>) Relative enrichment of select positive control (points) and all 1000 non-targeting control (NTC) sgRNAs (gray distribution) are plotted as a function of their log2 fold enrichment (‘high’ vs. ‘low’ bins). Data are from both replicate selections for each sgRNA (sgRNA denoted by shape). (<bold>D</bold>) Heatmap of β scores from CRISPR analysis, ordered according to k-means clustering (k = 8) of the 5% most enriched or depleted genes in each screen. (<bold>E</bold>) Macrophages were stimulated for 24 hr with TNF (25 ng/mL), IFNγ (10 ng/mL), or both TNF and IFNγ. Mean fluorescence intensity (MFI) of CD40 and MHCII was quantified by flow cytometry. Data are mean ± standard deviation for three biological replicates. Representative scatter plot from two independent experiments is provided. (<bold>F</bold>) Macrophages transduced with sgRNA targeting <italic>Stat1, Ostc, Cnbp</italic>, or a NTC were cultured with or without IFNγ for 24 hr, and cell surface expression of PD-L1 (MFI) was quantified by flow cytometry. For each genotype, data are the mean of cell lines with two independent sgRNAs ± standard deviation. Data are representative of three independent experiments. Statistical testing in panel (<bold>C</bold>) was performed with Tukey’s multiple comparisons test. Within each screen, the sgRNA effects for each gene were compared to the distribution of NTC sgRNAs. Statistical testing in panels (<bold>E</bold>) and (<bold>F</bold>) was performed by one-way ANOVA with Holm–Sidak multiple comparisons correction. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, *** and ****, respectively.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Whole-genome profiling of macrophage MHCII, CD40, and PD-L1 expression.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65109-fig1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>k-means clustering of CRISPR-KO beta scores for regulators of the IFNγ response.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65109-fig1-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig1-v2.tif"/></fig><p>To estimate the strength of selection on individual mutant cells, we specifically assessed the relative abundance of cells harboring sgRNAs that target each of the surface markers that were the basis for cell sorting. When the abundances of sgRNAs specific for <italic>H2-Ab1</italic> (encoding the MHCII, H2-I-A beta chain), <italic>Cd40</italic>, or <italic>Cd274</italic> (PD-L1) were compared between high- and low-expressing cell populations, we found that each of these sgRNAs were significantly depleted from the cell populations expressing the targeted surface molecule, while each had no consistent effect on the expression of non-targeted genes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). While not all individual sgRNAs produced an identical effect, we found that targeting the genes that served as the basis of sorting altered the mean relative abundance 30–60-fold, demonstrating that all selections efficiently differentiated responsive from non-responsive cells.</p><p>We next tested for statistical enrichment of sgRNAs using MAGeCK-MLE (<xref ref-type="bibr" rid="bib75">Li et al., 2015</xref>), which employs a generalized linear model to identify genes, and by extension regulatory mechanisms, controlling the expression of each surface marker. This analysis correctly identified the differential representation of sgRNAs targeting genes for the respective surface marker in the sorted populations in each screen, which were found in the top 20 ranked negative selection scores (ranks: <italic>H2-Ab1</italic> = 20, <italic>Cd40</italic> = 1, <italic>Cd274</italic> = 3; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Upon unsupervised clustering of selection coefficients determined by MAGeCK (β scores) for the most highly enriched genes in each screen (top 5%, positive or negative), both common and pathway-specific effects were apparent (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). A small number of genes assigned to cluster 1, including the IFNγ receptor components (<italic>Ifngr1</italic> and <italic>Ifngr2</italic>), were strongly selected in the non-responsive population of all three selections. However, many mutations appeared to preferentially affect the expression of individual surface markers, including a number of known pathway-specific functions. For example, genes previously shown to specifically control MHCII transcription, such as <italic>Ciita</italic>, <italic>Rfx5</italic>, <italic>Rfxap</italic>, <italic>Rfxank</italic>, and <italic>Creb1</italic> (<xref ref-type="bibr" rid="bib110">Steimle et al., 1994</xref>; <xref ref-type="bibr" rid="bib39">Ferwerda et al., 2005</xref>; <xref ref-type="bibr" rid="bib29">Chapoval et al., 2001</xref>; <xref ref-type="bibr" rid="bib111">Steimle et al., 1995</xref>), were found in cluster 4 along with several novel regulators that appear to be specifically required for this pathway. MHCII-specific factors are reported in an accompanying study (<xref ref-type="bibr" rid="bib67">Kiritsy et al., 2021</xref>).</p><p>Genes specifically required for CD40 expression in cluster 3 included the heterodimeric receptor for TNF. <italic>Tnfrsf1a</italic> and <italic>Tnfrsf1b</italic> were the 6th and 50th lowest β scores in the CD40 screen, respectively. Previous studies suggested that TNF stimulation enhances IFNγ-mediated CD40 expression in hematopoietic progenitors (<xref ref-type="bibr" rid="bib50">Gu et al., 2012</xref>), and we confirmed this observation in macrophages (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). We observed a six-fold higher induction of CD40 in macrophages stimulated with a combination of IFNγ and TNF compared to IFNγ alone. This synergy was specific to CD40 induction as we did not observe any enhancement of IFNγ-induced MHCII expression by TNF addition. While these results do not define the full TNF-related signaling pathway, they are consistent with the specific association between TNF receptor expression and CD40 induction.</p><p>Several recent studies have identified genes that control PD-L1 expression in cancer cell lines (<xref ref-type="bibr" rid="bib46">Garcia-Diaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Gong et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Mahoney et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Kataoka et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Burr et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Coelho et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Manguso et al., 2017</xref>; <xref ref-type="bibr" rid="bib85">Mezzadra et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Hassounah et al., 2019</xref>), and we validated the PD-L1-associated clusters using these candidates. Our analysis found the previously described negative regulators, <italic>Irf2</italic> (<xref ref-type="bibr" rid="bib70">Kriegsman et al., 2019</xref>), Keap1, and Cul3 (<xref ref-type="bibr" rid="bib95">Papalexi et al., 2020</xref>; <xref ref-type="bibr" rid="bib126">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="bib128">Wijdeven et al., 2018</xref>), in the PD-L1-related cluster 7, along with novel putative negative regulators such as the oligosaccharyltransferase complex subunit <italic>Ostc</italic> and the transcriptional regulator, <italic>Cnbp</italic>. We generated KO macrophages for each of these novel candidates and confirmed that mutation of these genes enhances the IFNγ-dependent induction of PD-L1 surface levels (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Cumulatively, these data delineate the complex regulatory networks that shape the IFNγ response.</p></sec><sec id="s2-2"><title>Mitochondrial complex I is a positive regulator of the IFNγ response</title><p>To identify global regulators of the IFNγ response, we performed a combined analysis, reasoning that treating each independent selection as a replicate measurement would increase our power to identify novel pathways. We again used MAGeCK to calculate a selection coefficient (β) for each gene by maximum likelihood estimation (<xref ref-type="bibr" rid="bib75">Li et al., 2015</xref>). By combining the 24 available measurements for each gene (three different markers, each selection in duplicate, and four sgRNAs per gene), we found that the resulting selection coefficient reflected the global importance of a gene for the IFNγ response (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). The most important positive regulators corresponded to the proximal IFNγ signaling complex (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similarly, we identified known negative regulators of IFNγ signaling, including the protein inhibitor of activated Stat1 (<italic>Pias1</italic>) (<xref ref-type="bibr" rid="bib76">Liu et al., 1998</xref>), protein tyrosine phosphatase non-receptor type 2 (<italic>Ptpn2</italic>) (<xref ref-type="bibr" rid="bib81">Manguso et al., 2017</xref>), mitogen activate protein kinase 1 (<italic>Mapk1</italic>), and suppressor of cytokine signaling 1 (<italic>Socs1</italic>) and 3 (<italic>Socs3</italic>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Global analysis of knockout (KO) libraries implicates mitochondrial complex I is a positive regulator of the IFNγ response.</title><p>(<bold>A</bold>) Rank plot of the combined analysis for all genome-wide KO screens. Gene ranks (x-axis) were determined by maximal likelihood estimation (MLE). Known positive (left) and negative (right) regulators of IFNγ-mediated signaling are highlighted. The q-value (false discovery rate [FDR]) for each gene is indicated by dot size (-log<sub>10</sub> FDR). (<bold>B</bold>) Gene set enrichment analysis (GSEA) is based on the ranked list of positive regulators. Non-redundant pathways with a normalized enrichment score (NES) exceeding 2.0 and an FDR below 0.025 are labeled. (<bold>C</bold>) Relative enrichment (log2 fold change between ‘high’ and “low” bins) of genes that comprise the mitochondrial respirasome (GeneOntology 0005746) and were targeted in the CRISPR KO library. Respirasome components are grouped by electron transport chain (ETC) complex. FDR is based on MAGeCK-MLE. (<bold>D</bold>) Screen-specific enrichment score is plotted for complex I structural subunits and assembly factors. The statistical enrichment of a gene (e.g., <italic>Ndufa1</italic>) or module (e.g., N) was calculated using a binomial distribution function to calculate the probability that observed sgRNAs under examination would be depleted or enriched given the expected median probability. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively. (<bold>E</bold>) Correlation between the relative effect of each complex I subunit on the structural integrity of the N-module (x-axis) with the relative requirement of each complex I subunit for the IFNγ response (y-axis; β score, as in panel <bold>D</bold>). The Pearson correlation coefficient (r) was calculated to be 0.6452 (95% confidence interval 0.3584–0.8207); p-value=0.0002. As <italic>Ndufab1</italic> (empty square) is an essential gene, its detection in the library indicates editing did not eliminate function; therefore, it was excluded from correlation analysis. (<bold>F</bold>) Following stimulation with IFNγ or PAM, extracellular acidification rate (ECAR)and (G) Oxygen consumption rate (OCR) values were measured by Seahorse in primary bone marrow-derived macrophages (BMDMs). Basal OCR and ECAR were determined 24 hr after stimulation with 10 ng/mL IFNγ or 200 ng/mL PAM. ****p&lt;0.0001 by one-way ANOVA. (H) In a parallel experiment, the indicated chemical modulators were added to resting (Black) or IFNγ-activated (Blue) BMDMs at the indicated time points after initiating metabolic monitoring and the OCR response was monitored. Basal OCR (blue box) and maximal OCR (red box) are highlighted (right panel). **p&lt;0.01 by two-tailed t-test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Whole-genome profiling of the IFNγ response in macrophages.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65109-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Gene set enrichment analysis (GSEA) to identify pathways that regulate the IFNγ response in macrophages.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65109-fig2-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig2-v2.tif"/></fig><p>We performed gene set enrichment analysis (GSEA) using a ranked list of positive regulators from the combined analysis (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>; <xref ref-type="bibr" rid="bib115">Subramanian et al., 2005</xref>). Among the top enriched pathways was a gene set associated with type II interferon (e.g., IFNγ) signaling (normalized enrichment score = 2.45, q-value = 7.98e-5) validating the approach. GSEA identified a similarly robust enrichment for gene sets related to mitochondrial respiration and oxidative phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In particular, we found a significant enrichment of gene sets dedicated to the assembly and function of the NADH:ubiquinone oxidoreductose (hereafter, ‘complex I’) of the mitochondrial respiratory chain. Complex I couples electron transport with NADH oxidation and is one of four protein complexes that comprise the electron transport chain (ETC) that generates the electrochemical gradient for ATP biosynthesis. To confirm the GSEA results, we examined the combined dataset for individual genes that make up each complex of the ETC (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). This analysis failed to demonstrate a clear role for sgRNAs targeting components of complexes II, III, or IV in the expression of the IFNγ-inducible surface markers tested. In contrast, the disruption of almost every subunit of complex I impaired the response to IFNγ, with the notable exception of <italic>Ndufab1</italic>. As this gene is essential for viability (<xref ref-type="bibr" rid="bib112">Stroud et al., 2016</xref>), we assume that cells carrying <italic>Ndufab1</italic> sgRNAs retain functional target protein.</p><p>To investigate the contribution of specific complex I components to different IFNγ-stimulated phenotypes, we reviewed the surface marker-specific enrichment scores for genes that contribute to the complex assembly, the electron-accepting N-module, or the electron-donating Q module (<xref ref-type="bibr" rid="bib112">Stroud et al., 2016</xref>; <xref ref-type="bibr" rid="bib72">Lazarou et al., 2007</xref>; <xref ref-type="bibr" rid="bib93">Pagliarini et al., 2008</xref>; <xref ref-type="bibr" rid="bib7">Baradaran et al., 2013</xref>; <xref ref-type="bibr" rid="bib132">Zickermann et al., 2015</xref>; <xref ref-type="bibr" rid="bib131">Zhu et al., 2016</xref>). Of the 42 individual assembly factors or structural subunits of complex I present in our mutant library, 29 were significantly enriched as positive regulators in the global analysis and were generally required for the induction of all IFNγ-inducible markers (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The enrichment for each functional module in non-responsive cells was statistically significant. However, not all individual complex I components were equally enriched, which could reflect either differential editing efficiency or distinct impacts on function. To investigate the latter hypothesis, we compared our genetic data with a previous proteomic study that quantified the effect of individual complex I subunits on the stability of the largest subcomplex, the N-module (<xref ref-type="bibr" rid="bib112">Stroud et al., 2016</xref>). For a given subunit, we found a significant correlation between the magnitude of enrichment in our genetic screen and its effect on the structural stability of the module (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), specifically implicating the activity of complex I in the IFNγ response.</p><p>These genetic data suggested a role for oxidative phosphorylation (OXPHOS) in the IFNγ response. To verify the mechanism of energy generation utilized by IFNγ-treated cells, we measured both their OXPHOS-dependent oxygen consumption rate (OCR) and glycolysis-dependent extracellular acidification rate (ECAR). IFNγ or toll-like receptor (TLR) 2 stimulation with Pam3CSK4 produced similar overall metabolic effects, increasing both OCR and ECAR in these cells (<xref ref-type="fig" rid="fig2">Figure 2F,G</xref>). Further analysis of mitochondrial function revealed that IFNγ increased both the basal and maximal OCR that was observed upon decoupling electron transport from ATP generation (<xref ref-type="fig" rid="fig2">Figure 2H</xref>) with carbonyl cyanide-4-trifluoromethoxy phenylhydrazone (FCCP).</p><p>To directly test the role of OXPHOS in the IFNγ response, we used CRISPR to generate individual macrophage lines that were deficient for complex I subunits. We first validated the expected metabolic effects of complex I disruption by comparing the intracellular ATP levels in macrophages carrying non-targeting control sgRNA (sgNTC) with sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic> lines. When cultured in media containing the glycolytic substrate, glucose, all cell lines produced equivalent amounts of ATP (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). However, when pyruvate was provided as the sole carbon source and ATP generation depended entirely upon flux through ETC and OXPHOS, both sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic> macrophages contained decreased ATP levels compared to sgNTC cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To confirm the glycolytic dependency of complex I mutant macrophages, we grew cells in complete media with glucose and treated with the ATP synthase (complex V) inhibitor, oligomycin, which blocks ATP generation by OXPHOS. While oligomycin reduced ATP levels in sgNTC macrophages, this treatment had no effect in sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic> cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), confirming that these complex I-deficient cells rely on glycolysis for energy generation. IFNγ treatment slightly reduced ATP levels in glucose-containing media but did not differentially affect cell lines (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Throughout these experiments, we found that the sg<italic>Ndufa1</italic> mutant showed a greater OXPHOS deficiency than the sg<italic>Ndufa2</italic> line.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Complex I is necessary for IFNγ-induced MHCII and PD-L1 expression.</title><p>Metabolic phenotypes in macrophage mutants were confirmed by measuring intracellular (IC) ATP abundance following culture in media containing only (<bold>A</bold>) glucose or (<bold>B</bold>) pyruvate. Values are normalized to the average respiratory capacity of non-targeting control macrophages (NTC) and are the mean ± standard deviation for four biological replicates. Statistical testing within each condition (with or without IFNγ for 24 hr) was performed by one-way ANOVA with Dunnett’s multiple comparisons correction. (<bold>C–F</bold>) NTC, positive control (sg<italic>Ifngr1</italic> and sg<italic>Ptpn2</italic>), and complex I mutant (sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic>) macrophages were stimulated for 24 hr with recombinant murine IFNγ. Plotted values in (<bold>C</bold>) and (<bold>E</bold>) are the geometric mean fluorescence intensity (MFI) for a given mutant normalized to an internal control present in each well; for each gene, the data are the mean for two independent sgRNAs ± standard deviation. Representative histograms are provided in (<bold>D</bold>) and (<bold>F</bold>). Data are representative of &gt;5 independent experiments. (<bold>G</bold>) MHCII MFI of macrophages stimulated with IFNγ and treated with rotenone at the indicated concentrations for 24 hr. Mean ± standard deviation for two biological replicates are shown. Data are representative of four independent experiments. (<bold>H</bold>) Left: MHCII MFI on macrophages cultured in complete media (CM) and stimulated with IFNγ and the indicated inhibitors for 24 hr. Right: MHCII MFI on macrophages cultured in CM or media containing only pyruvate (Pyr) or citrate (Cit) stimulated with IFNγ for 24 hr. Mean ± standard deviation for two or three biological replicates is indicated. Data are representative of four independent experiments. Statistical testing was performed by one-way ANOVA with Tukey’s correction for multiple hypothesis testing. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The complex I dependency of IFNγ signaling is independent of reactive oxygen and nitrogen radicals, and Hif-1α.</title><p>(<bold>A</bold>) sgNTC, sg<italic>Ndufa1</italic>, and sg<italic>Ndufa2</italic> cells cultured in complete media and treated with or without oligomycin (2.5 μM) for 4 hr. Relative ATP levels were determined as in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. (<bold>B</bold>) Intracellular ATP levels quantified as relative light units (RLUs) using CellTiter-Glo2.0 (Promega) for macrophages in specified growth conditions for 4 hr. Concentrations of carbon source and inhibitors are indicated in Materials and methods. (<bold>C</bold>) sgNTC macrophages were grown in glucose then treated with DMSO, rotenone (10 µM), antimycin A (10 µM), and sodium azide (10 mM) for 24 hr, and the reduction in ATP was quantified using CellTiter-Glo2.0. (<bold>D</bold>) In parallel, sample cells were left resting or were stimulated with IFNγ and the surface expression of MHCII was quantified by flow cytometry. (<bold>E</bold>) Macrophages were cultured in either glucose or galactose and stimulated with IFNγ for 24 hr. Following stimulation, the proportion of cells with MHCII expression was determined by flow cytometry. (<bold>F</bold>) Macrophages were cultured in conditions as described in <xref ref-type="fig" rid="fig4">Figure 4H</xref>. For each condition, cells were stimulated with IFNγ or IFNγ and N-acetyl cysteine (NAC) for 24 hr after which cell surface levels of MHCII were quantified. (<bold>G</bold>) Control or complex I mutant (sg<italic>Ndufa2</italic>) macrophages were stimulated with IFNγ for 24 hr with increasing doses of mitochondrial reactive oxygen species scavenger MitoTEMPO. For each concentration, values are plotted as a fold change relative to no scavenger; Mean ± standard deviation for two biological replicates of each condition. (<bold>H</bold>) Control or complex I-deficient macrophages were stimulated with IFNγ for 24 hr with or without the addition of dimethyloxalylglycine (DMOG) or 1400W. Following stimulation, the proportion of cells with MHCII expression was determined by flow cytometry. (<bold>I</bold>) Nitric oxide was measured using Griess Reagent System (Promega) from cell supernatants following stimulation with IFNγ and Pam3CSK4 for 24 hr with or without the addition of DMOG or 1400W. Relative nitric oxide levels were calculated as a percent relative to control (IFNγ and Pam3CSK4 with DMSO). All data are representative of at least two independent experiments. Statistical testing was performed using one-way ANOVA with Holm–Sidak multiple comparison correction. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We next compared the response to IFNγ in macrophages lacking <italic>Ndufa1</italic> and <italic>Ndufa2</italic> with those carrying CRISPR-edited alleles of <italic>Ifngr1</italic> or the negative regulator of signaling, <italic>Ptpn2</italic>. As CD40 was found to rely on more complex inputs for expression, which include TNF (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), we relied on MHCII and PD-L1 as markers of the IFNγ response for subsequent studies. As expected, and consistent with the genetic screen, we found that the loss of <italic>Ifngr1</italic> or <italic>Ptpn2</italic> either abrogated or enhanced the response to IFNγ, respectively. Also consistent with predictions, mutation of complex I genes significantly reduced the IFNγ-dependent induction of MHCII and PD-L1 compared to sgNTC (<xref ref-type="fig" rid="fig3">Figure 3C–F</xref>). The <italic>Ndufa1</italic> mutation that abolishes OXPHOS reduced MHCII induction to the same level as <italic>Ifngr1</italic>-deficient cells. To confirm these results using an orthologous method, we treated cells with the complex I inhibitor, rotenone (<xref ref-type="bibr" rid="bib8">Barrientos and Moraes, 1999</xref>). This treatment caused a dose-dependent inhibition of the IFNγ-induced MHCII expression in sgNTC macrophages (<xref ref-type="fig" rid="fig3">Figure 3G</xref>) and had a similar inhibitory effect on the residual IFNγ response in <italic>Ndufa2</italic>-deficient cells. Together, these results confirm that complex I is required for the induction of immunomodulatory surface molecules in response to IFNγ.</p><p>To determine which aspect of mitochondrial respiration contributes to the IFNγ response, we inhibited different components of the ETC. Rotenone, oligomycin, and carbonyl cyanide m-chlorophenyl hydrazone (CCCP) were used at concentrations that abolished the OXPHOS-dependent ATP generation that is necessary in pyruvate media (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). The complex V inhibitor, oligomycin, inhibited the IFNγ-induced MHCII expression, albeit to a lesser extent than direct complex I inhibition with rotenone (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). This partial effect could reflect an inability to dissipate the proton motive force (PMF), which inhibits electron flux throughout the ETC, including through complex I (<xref ref-type="bibr" rid="bib17">Brand and Nicholls, 2011</xref>). CCCP disrupts mitochondrial membrane potential and OXPHOS while preserving electron flux. CCCP had no effect on the IFNγ response, indicating that ATP generation is dispensable for IFNγ responsiveness and highlighting a specific role for complex I activity. To directly test the contributions of complex III and IV to the IFNγ response, we inhibited each complex using antimycin A and sodium azide, respectively. While treatment with these inhibitors lowered ATP concentration similarly to rotenone in glucose-containing media (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), the effect of complex III or IV inhibition on IFNγ-mediated MHCII expression was less than rotenone treatment and was similar to the partial inhibition observed with oligomycin (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). These observations are consistent with the initial screen, where complex I inhibition produced the most pronounced effect on the IFNγ response.</p><p>We then altered the media composition to test the sufficiency of mitochondrial respiration to drive IFNγ responses independently from aerobic glycolysis. IFNγ was found to stimulate MHCII expression to a similar degree in macrophages cultured in complete media with glucose as in media containing only pyruvate or citrate, which must be catabolized via mitochondrial respiration (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Taken together these results suggest that cellular respiration is both necessary and sufficient for maximal expression of the IFNγ-inducible surface markers MHCII and PD-L1.</p></sec><sec id="s2-3"><title>Mitochondrial function is specifically required for IFNγ-dependent responses</title><p>The mitochondrial dependency of the IFNγ response contrasted with the known glycolytic dependency of TLR signaling, suggesting that TLR responses would remain intact when complex I was inhibited. Indeed, not only were TLR responses intact in sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic> mutant macrophages, these cells secreted larger amounts of TNF or interleukin 6 (IL-6) than sgNTC cells in response to the TLR2 ligand, Pam3CSK4. (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Thus, the glycolytic dependency of these cells enhanced the TLR2 response, indicating opposing metabolic dependencies for IFNγ and TLR signaling.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Diminished mitochondrial function specifically limits IFNγ-dependent responses.</title><p>(<bold>A</bold>) TNF and IL-6 production by non-targeting control (NTC) or complex I mutant macrophages stimulated with Pam3CSK4 for 24 hr was determined by ELISA. Statistical testing between mutant and NTC macrophages from triplicate samples was performed by ANOVA with Dunnett’s correction for multiple comparisons. Data are representative of two independent experiments. (<bold>B</bold>) qPCR determination of relative mitochondrial genomes present per nuclear genome in macrophages cultured in vehicle (WT) or 50 µg/mL linezolid (LZD). C<sub>t</sub> values were normalized to reference nuclear gene hexokinase 2 (<italic>Hk2</italic>) and plotted as abundance relative to WT. Data were analyzed by two-way unpaired t-test. (<bold>C</bold>) ATP abundance in control or LZD-conditioned macrophages cultured in 10 mM glucose, galactose, or pyruvate. ATP values normalized to mean of 10 mM glucose and plotted as percent. Mean ± standard deviation for two biological replicates of each condition. Differences were tested by two-way ANOVA using the Sidak method to correct for multiple hypothesis testing. (<bold>D</bold>) Mean fluorescence intensity (MFI) of MHCII was determined by flow cytometry on control or LZD-conditioned macrophages following 24 hr stimulation with IFNγ. Mean ± standard deviation for two biological replicates of each condition and representative of two independent experiments. Differences were tested by two-way ANOVA using Tukey’s method to correct for multiple hypothesis testing. (<bold>E, F</bold>) Secretion of TNF and IL-6 in WT and LZD-conditioned macrophages following Pam3CSK4 stimulation for 6 hr was quantified by ELISA. Mean ± standard deviation for three biological replicates of each condition and two independent experiments. Data were analyzed by two-way unpaired t-test. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig4-v2.tif"/></fig><p>Whether the effect of complex I on macrophage responsiveness was the result of reduced mitochondrial respiratory function or secondary to cellular stress responses, such as radical generation, remained unclear. To more directly relate mitochondrial function to these signaling pathways, we created cell lines with reduced mitochondrial mass. Macrophages were continuously cultured in linezolid (LZD), an oxazolidinone antibiotic that inhibits the mitochondrial ribosome (<xref ref-type="bibr" rid="bib34">De Vriese et al., 2006</xref>; <xref ref-type="bibr" rid="bib109">Soriano et al., 2005</xref>; <xref ref-type="bibr" rid="bib129">Wilson et al., 2008</xref>). This treatment produced a cell line with ~50% fewer mitochondrial genomes per nuclear genome and a corresponding decrease in OXPHOS capacity compared to control cells grown in the absence of LZD (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Cells were cultured without LZD for 16 hr and then stimulated with either IFNγ or Pam3CSK4. Consistent with our complex I inhibition studies, we found that this reduction in mitochondrial mass nearly abrogated the IFNγ-dependent induction of MHCII (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), while the TLR2-dependent secretion of TNF and IL-6 was preserved or enhanced (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). Thus, mitochondrial activity, itself, is necessary for a robust IFNγ response.</p><p>To further address potential secondary effects of mitochondrial inhibition on the IFNγ response, we investigated the role of known oxygen or nitrogen radical-dependent regulators (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E–I</xref>). Inhibition of ROS generation by replacing glucose with galactose (<xref ref-type="bibr" rid="bib125">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Brand and Nicholls, 2011</xref>; <xref ref-type="bibr" rid="bib23">Bustamante et al., 1978</xref>) had no effect on IFNγ-induced MHCII induction. Similarly, neutralization of cytosolic or mitochondrial radicals with N-acetyl cysteine (NAC) or MitoTEMPO, respectively, had no effect on MHCII induction either alone or in combination with ETC inhibition. The role of the cytosolic redox sensor, HIF-1α (<xref ref-type="bibr" rid="bib33">Cramer et al., 2003</xref>; <xref ref-type="bibr" rid="bib106">Semenza, 2012</xref>), was addressed by chemically stabilizing this factor with dimethyloxalylglycine (DMOG). A potential role for nitric oxide production was addressed with the specific NOS2 inhibitor 1400W (<xref ref-type="bibr" rid="bib37">Everts et al., 2012</xref>; <xref ref-type="bibr" rid="bib125">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Braverman and Stanley, 2017</xref>). Neither of these treatments affected IFNγ-induced MHCII cell surface expression in the presence or absence of simultaneous Pam3CSK4, further supporting a direct relationship between mitochondrial respiratory capacity and the IFNγ response.</p></sec><sec id="s2-4"><title>Complex I is specifically required for IFNγ signaling in human cells</title><p>To understand the function of complex I during IFNγ stimulation in human cells, we used monocyte-derived macrophages (MDMs) from peripheral blood of healthy donors differentiated in the presence of GM-CSF. As in our mouse studies, we assessed the response of these cells to IFNγ or Pam3CSK4 by quantifying the abundance of IFNγ-inducible surface markers or cytokines that were optimized for human cells. Since HLA-DR is not strongly induced by IFNγ, we included ICAM1 in addition to CD40 and PD-L1 as surface markers. As seen in the murine model, rotenone inhibited the IFNγ-mediated induction of all three markers (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Similar results were obtained using CD14+ monocytes and M-CSF-derived macrophages (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). TLR2 responses were assessed by the production of TNF and IL-1β. Upon Pam3CSK4 stimulation of GM-CSF-derived MDM, rotenone significantly enhanced the secretion of IL-1β and TNF (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). While simultaneous treatment with both IFNγ and Pam3CSK4 produced the previously described inhibition of IL-1β (<xref ref-type="bibr" rid="bib89">Mishra et al., 2013</xref>), rotenone still did not decrease the production of these TLR2-dependent cytokines. Thus, as we observed in mouse cells, complex I is specifically required for IFNγ signaling in human macrophages.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Complex I is specifically required for IFNγ signaling in human cells.</title><p>(<bold>A</bold>) CD14+ monocytes from healthy human donors were differentiated into macrophages with GM-CSF. Mean fluorescence intensity (MFI) of cell surface markers PD-L1, ICAM1, CD40, and HLA-DR was determined by flow cytometry following stimulation with IFNγ and/or inhibition of complex I with rotenone (10 µM) for 24 hr. Data are representative of two independent experiments, and values are normalized to donor-specific unstimulated/vehicle control. Mean ± standard deviation for six biological replicates of each condition. Differences were tested by two-way ANOVA using the Sidak–Holm method to correct for multiple hypothesis testing. (<bold>B, C</bold>) Quantification of IL-1β and TNF production from primary human macrophages, measured by ELISA from cell supernatants following stimulation. Lines connect values for individual donors treated with vehicle (DMSO, black squares) or rotenone (empty squares). Differences were tested by repeated measures two-way ANOVA using the Sidak–Holm method to correct for multiple hypothesis testing. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Complex I is specifically required for IFNγ signaling in diverse human myeloid cells.</title><p>CD14+ monocytes were isolated from healthy human donors and stimulated directly (upper panel) or subsequent to differentiation into macrophages with M-CSF (lower panel). Mean fluorescence intensity (MFI) of cell surface markers PD-L1, ICAM1, CD40, and HLA-DR was determined by flow cytometry following stimulation with IFNγ and/or inhibition of complex I with rotenone (10 µM) for 24 hr. Data are representative of two independent experiments, and values are normalized to donor-specific unstimulated/vehicle control. Mean ± standard deviation for six biological replicates of each condition. Differences were tested by two-way ANOVA using the Sidak–Holm method to correct for multiple hypothesis testing. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Complex I inhibition reduces IFNγ receptor activity</title><p>To understand how complex I activity shapes the IFNγ response, we determined whether its effect was transcriptional or post-transcriptional by simultaneously monitoring mRNA and protein abundance over time. Surface expression of PD-L1 was compared with Cd274 mRNA abundance, while the surface expression of MHCII was compared with the mRNA abundance of <italic>Ciita</italic>, the activator of MHCII expression that is initially induced by IFNγ (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). In both cases, mRNA induction preceded surface expression of the respective protein. More importantly, both mRNA and protein expression of each marker were diminished to a similar degree in sg<italic>Ndufa1</italic> and sg<italic>Ndufa2</italic> compared to sgNTC cells. Thus, a deficit in transcriptional induction could account for the subsequent decrease in surface expression observed in complex I deficient cells.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Complex I inhibition reduces IFNγ receptor activity.</title><p>(<bold>A</bold>) PD-L1 transcript was quantified by qRT-PCR using ΔΔCt relative to <italic>β-actin</italic> in macrophages of the indicated genotype after stimulation with 10 ng/mL IFNγ. PD-L1 mean fluorescence intensity (MFI) was determined at the same time points by flow cytometry. (<bold>B</bold>) <italic>Ciita</italic> transcript was quantified by qRT-PCR using ΔΔCt relative to <italic>β-actin Gapdh</italic> in macrophages of the indicated genotype after stimulation with 10 ng/mL IFNγ. MHCII MFI was determined at the same time points by flow cytometry. Data shown are from biological triplicate samples with technical replicates for RT-PCR experiments and are representative of two independent experiments. (<bold>C</bold>) sgNTC (left) or sg<italic>Irf1</italic> (right) macrophages were cultured for 24 hr with or without IFNγ stimulation. At 2 hr intervals post-IFNγ stimulation, rotenone was added. After 24 hr of stimulation, cells were harvested and surface expression of MHCII (MFI) was quantified by flow cytometry. Data are mean ± standard deviation for three biological replicates and are representative of two independent experiments. Statistical testing was performed by one-way ANOVA with Tukey’s correction for multiple hypothesis testing. (<bold>D</bold>) Control (non-targeting control [NTC]) or sg<italic>Ndufa1</italic> macrophages were stimulated with IFNγ for the indicated times while NTC macrophages were pretreated with 10 μM rotenone for 2 hr prior to IFNγ stimulation. Cell lysates analyzed by immunoblot for STAT1 abundance and phosphorylation (Y701 and S727), JAK2 abundance and phosphorylation (Y1007/8), and IFNGR1. β-Actin was used as a loading control. Data are representative of three independent experiments. Results shown are from a single experiment analyzed on three parallel blots. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw blots.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-65109-fig6-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Labeled raw blots.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-65109-fig6-data2-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig6-v2.tif"/></fig><p>IFNγ rapidly induces the transcription of a large number of STAT1 target genes, including <italic>Irf1</italic>, which amplifies the response. The relative impact of complex I inhibition on the immediate transcriptional response versus the subsequent IRF1-dependent amplification was initially assessed by altering the timing of complex I inhibition. As the addition of rotenone was delayed relative to IFNγ stimulation, the ultimate effect on MHCII expression was diminished (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). If rotenone was added more than 4 hr after IFNγ, negligible inhibition was observed by 24 hr, indicating that early events were preferentially impacted by rotenone. To more formally test the role of IRF1, this study was performed in macrophages harboring a CRISPR-edited <italic>Irf1</italic> gene. While the level of MHCII induction was reduced in the absence of IRF1, the relative effect of rotenone addition over time was nearly identical in sg<italic>Irf1</italic> and sgNTC cells. Thus, mitochondrial function appeared to preferentially impact the initial transcriptional response to IFNγ upstream of IRF1.</p><p>Ligand-induced assembly of the IFNGR1-IFNGR2 receptor complex results in the phosphorylation and transactivation of janus kinases 1 and 2 (JAK1 and JAK2). Autophosphorylation of JAK2 at tyrosine residues 1007/1008 positively regulates this cascade and serves as a marker of JAK2 activation. These activating events at the cytoplasmic domains of the IFNγ receptor complex facilitate STAT1 docking and phosphorylation at tyrosine-701 (Tyr701), a prerequisite for the IFNγ response. Additional STAT1 phosphorylation at serine-727 (Ser727) can amplify signaling. To determine if complex I is required for these early signal transduction events, we examined the activation kinetics by immunoblot (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The total abundances of IFNGR1, STAT1, and JAK2, were constant in sgNTC and sg<italic>Ndufa1</italic> cells in the presence and absence of IFNγ stimulation. While we detected robust phosphorylation of JAK2 Y1007/8, STAT1-Y701, and STAT1-S727 over time following IFNγ treatment in sgNTC cells, phosphorylation at all three sites was both delayed and reduced across the time course in sg<italic>Ndufa1</italic> cells. We conclude that the loss of complex I function inhibits receptor proximal signal transduction events.</p></sec><sec id="s2-6"><title>Mitochondrial respiration in APCs is required for IFNγ-dependent T cell activation</title><p>As respiration affected both stimulatory and inhibitory APC functions, we sought to understand the ultimate effect of mitochondrial function on T cell activation. To this end, we generated myeloid progenitor cell lines from Cas9-expressing transgenic mice that can be used for genome-editing and differentiated into either macrophages or DCs using M-CSF or FLT3L, respectively (<xref ref-type="bibr" rid="bib124">Wang et al., 2006</xref>; <xref ref-type="bibr" rid="bib98">Redecke et al., 2013</xref>). Macrophages differentiated from these myeloid progenitors demonstrated robust induction of all three markers that were the basis for the IFNγ stimulation screens (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–C</xref>). Further, both the IFNγ-mediated upregulation of these markers and the inhibitory effect of rotenone or oligomycin on their induction were indistinguishable from wild type primary BMDMs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D–F</xref>). In both macrophages and in DCs, the induction of MHCII by IFNγ was inhibited by rotenone and oligomycin (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Unlike macrophages, murine DCs basally express MHCII and these inhibitors only repressed the further induction by IFNγ (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mitochondrial respiration in antigen-presenting cells (APCs) is required for IFNγ-dependent T cell activation.</title><p>(<bold>A</bold>) Cell surface expression of MHCII (mean fluorescence intensity [MFI]) in macrophages (MF) or dendritic cells (DCs) derived from conditionally immortalized progenitor lines. IFNγ was added for 24 hr where indicated. Cells were treated with vehicle (DMSO), rotenone (10 µM), oligomycin (OM, 2.5 µM), or carbonyl cyanide m-chlorophenyl hydrazone (CCCP) concurrent with IFNγ. Data are three biological replicates and are representative of at least two independent experiments. (<bold>B</bold>) Contour plot of macrophage (top row) or DC (bottom row) MHCII expression in the absence of (left column) or following (right column) stimulation with IFNγ for 24 hr. Representative samples were selected from (<bold>A</bold>). The percent MHCII positive are indicated for each of the conditions. (<bold>C</bold>) CD4+ T cell activation as measured by the percent of live cells positive for IFNγ by intracellular cytokine staining. Prior to co-culture with T cells, APCs were stimulated with the indicated combinations of IFNγ (10 ng/mL), and/or rotenone (10 µM) for 24 hr. After washing and pulsing with ESAT-61–15 at the indicated concentrations (nm), T cells were added to APCs at an effector to target (E:T) ratio of 1:1 and co-cultured for a total of 5 hr. Data are representative of two independent experiments. Data are mean ± standard deviation for three biological replicates. Statistical testing was performed by one-way ANOVA with Tukey’s correction for multiple hypothesis testing. (<bold>D, E</bold>) sg<italic>Ndufa1</italic> or non-targeting control (NTC) macrophages were differentiated from immortalized progenitors and mixed at the ratios indicated (labeled as percent of knockout [KO] cells). Mixed cultures were stimulated with IFNγ for 24 hr, peptide loaded, and co-cultured with CD4+ T cells (E:T 1:1). Production of IFNγ was measured by ICS and quantified as the percent of cells positive for staining by flow cytometry. Representative contour plots (<bold>D</bold>) and quantification (<bold>E</bold>) of the experiment are shown. Data shown are for biological triplicate samples and are representative of two independent experiments. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>The metabolic dependencies for IFNγ signaling are preserved in macrophages derived from myeloid progenitor lines.</title><p>(<bold>A–C</bold>) Myeloid progenitors cells were conditionally immortalized by transducing murine bone marrow with an estrogen-dependent Hoxb8 transgene that maintains stem-like properties. Following differentiation of progenitors into macrophages using M-CSF-enriched conditioned media, macrophages were stimulated with IFNγ with or without rotenone. 24 hr after stimulation, cell surface levels of (<bold>A</bold>) MHCII, (<bold>B</bold>) CD40, and (<bold>C</bold>) PD-L1 were quantified by flow cytometry. Data are representative of three independent experiments and are the mean ± standard deviation for two biological replicates. Statistical testing was performed by one-way ANOVA with Tukey’s correction for multiple hypothesis testing. (<bold>D–F</bold>) As in panels (<bold>A–C</bold>), macrophages from either immortalized macrophage progenitors or primary bone marrow were stimulated with IFNγ with or without rotenone or oligomycin. 24 hr after stimulation, cell surface levels of (<bold>D</bold>) MHCII, (<bold>E</bold>) CD40, and (<bold>F</bold>) PD-L1 were quantified by flow cytometry. (<bold>G</bold>) Wild-type or ΔNdufa1 macrophages derived from Hoxb8-immortalized bone marrow progenitors were cultured in the specified media and inhibitor condition before total intracellular ATP was quantified by CellTiter-Glo2.0. For each genotype, values are relative to ‘glucose’ control. Mean ± standard deviation for two biological replicates of each condition. p-Values of 0.05, 0.01, 0.001, and 0.001 are indicated by *, **, ***, and ****, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-65109-fig7-figsupp1-v2.tif"/></fig></fig-group><p>Both macrophages and DCs were used to determine if the inhibition of complex I in APCs reduces T cell activation. Both types of APCs were stimulated with IFNγ overnight with or without rotenone before washing cells to remove rotenone and ensure T cell metabolism was unperturbed. APCs were then pulsed with a peptide derived from the <italic>Mycobacterium tuberculosis</italic> protein ESAT-6 and co-cultured with ESAT-6-specific CD4+ T cells from a TCR transgenic mouse (<xref ref-type="bibr" rid="bib45">Gallegos et al., 2008</xref>). T cell activation was assayed by intracellular cytokine staining for IFNγ. In macrophages, T cell stimulation relied on pretreatment of the APC with IFNγ as a macrophage line lacking the <italic>Ifngr1</italic> gene was unable to support T cell activation. Similarly, inhibition of complex I in macrophages completely abolished antigen-specific T cell stimulation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). DCs did not absolutely require IFNγ pretreatment to stimulate T cells, likely due to the basal expression of MHCII by these cells. Regardless, rotenone treatment of DCs abrogated the IFNγ-dependent increase in T cell stimulation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p><p>To confirm the effects of complex I inhibition on T cell activation using a genetic approach and confirm that complex I inhibition acted in a cell-autonomous mechanism, we generated <italic>Ndufa1</italic> KO myeloid progenitors (Hox-sg<italic>Ndufa1</italic>). Following differentiation into macrophages, Hox-sg<italic>Ndufa1</italic> demonstrated glycolytic dependence and an inability to generate ATP by OXPHOS compared to control Hox-sgNTC macrophages (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1G</xref>). Having confirmed the expected metabolic effects of Ndufa1 loss, Hox-sg<italic>Ndufa1</italic> and Hox-sgNTC macrophages were mixed at various ratios. Mixed cultures were then stimulated with IFNγ, peptide pulsed, and co-cultured with antigen-specific CD4+ T cells. In agreement with our chemical inhibition studies, we found strong correlation between complex I activity in the APC population and T cell stimulatory activity (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>). Together, these data confirm that the IFNγ-dependent augmentation of T cell stimulatory activity depends on complex I function in both macrophages and DCs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>IFNγ-mediated control of APC function is central to shaping a protective immune response, and the canonical IFNγ signal transduction pathway has been elucidated in exquisite detail (<xref ref-type="bibr" rid="bib11">Bhat et al., 2018</xref>). Our study demonstrates that unbiased genetic analyses can reveal a multitude of unexpected cellular regulators, even for a well-characterized process such as IFNγ signaling. By independently assessing genetic determinants of stimulatory and inhibitory molecule expression, we discovered mechanisms of regulation that preferentially affect the induction of different cell surface proteins. These results begin to explain how a single cytokine can induce functionally distinct downstream responses in different contexts. These data also suggest new strategies to modulate individual co-receptors to either stimulate or inhibit T cell activation. Another strength of our parallel screen approach was the increased power to identify shared mechanisms that control IFNγ-mediated regulation across all screens. Our pooled analysis identified mitochondrial respiration, and in particular complex I, as essential for IFNγ responses in APCs. We determined that complex I is required for the IFNγ-mediated induction of important co-signaling molecules and is necessary for antigen presentation and T cell activation. These findings uncover a new dependency between cellular metabolism and the immune response.</p><p>Both our work and others report that IFNγ stimulation alters macrophage metabolism. We found that IFNγ stimulation increases oxygen consumption and glycolytic activity, and previous studies found that this treatment mediates a gradual shift to aerobic glycolysis that might be related to a reduction in mTORC1 activity (<xref ref-type="bibr" rid="bib125">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Su et al., 2015</xref>). While the overall effect of IFNγ on cellular metabolism appears to be complex and change over time, our genetic data unequivocally reveal that mitochondrial respiration is required for IFNγ signaling. Data from the CRISPR screens suggested a preferential role for complex I, relative to complexes II, III, or IV. Further chemical inhibitor studies showed that blocking complex III, IV, or V (ATP synthase) does reduce IFNγ responses, but not to the same magnitude as complex I inhibition. These data could suggest that complex I is still able to support IFNγ signaling in the absence of these downstream complexes, perhaps by transferring electrons to an alternative acceptor. Additional work is necessary to elaborate the structure of the ETC in these cells and potential interactions with mTORC1.</p><p>Complex I is a metabolic hub with several core functions that cumulatively recycle nicotinamide adenine dinucleotide (NAD+), reduce ubiquinol, and initiate the PMF for ATP generation. While any or all of these physiological processes could contribute to IFNγ signaling, the differential effects of chemical inhibitors narrow the possibilities. Both rotenone and oligomycin inhibit the IFNγ response, and block electron flux through complex I, either directly or indirectly. In contrast, the ionophore CCCP disrupts the PMF and ATP generation without inhibiting electron transfer and does not affect IFNγ signaling. These observations indicate that the reduction state of the quinone pool and ATP generation does not regulate IFNγ responses in our system. Instead, our data indicate that complex I-dependent regeneration of NAD+ is the most likely regulator of IFNγ signaling. Indeed, NAD+ synthesis via either the de novo or salvage pathway is necessary for a variety of macrophage functions (<xref ref-type="bibr" rid="bib26">Cameron et al., 2019</xref>; <xref ref-type="bibr" rid="bib122">Venter et al., 2014</xref>; <xref ref-type="bibr" rid="bib88">Minhas et al., 2019</xref>). Very recent work demonstrates an important role for NAD+ in STAT1 activation and PD-L1 induction by IFNγ in hepatocellular carcinoma cells (<xref ref-type="bibr" rid="bib78">Lv et al., 2021</xref>). In this setting, inhibition of NAD+ synthesis reduces the abundance of phospho-STAT1 by disrupting a direct interaction with the ten-eleven translocation methylcytosine dioxygenase 1 (TET1). It remains unclear if a similar interaction occurs in the myeloid cells that are the focus of our work, as TET1 is expressed at very low levels in macrophages and splenic DCs (<xref ref-type="bibr" rid="bib53">Heng et al., 2008</xref>). Regardless, these observations suggest that both NAD+ synthesis and its regeneration via mitochondrial respiration contribute to the IFNγ response in diverse cell types. This recently revealed interaction between metabolism and immunity could contribute to the observed association between NAD+ homeostasis and inflammatory diseases (<xref ref-type="bibr" rid="bib88">Minhas et al., 2019</xref>), as well as the efficacy of checkpoint inhibitor therapy for cancer (<xref ref-type="bibr" rid="bib78">Lv et al., 2021</xref>).</p><p>In the APC setting, we found that T cell activation required mitochondrial respiration. While complex I function, MHCII, and CD40 expression all largely correlate with T cell stimulation, our data indicate that additional IFNγ-inducible pathways also contribute to this activity. For example, unstimulated DCs basally express similar levels of MHCII as IFNγ-stimulated macrophages but are unable to productively present antigen to T cells. This observation suggests that additional aspects of antigen processing, presentation, or co-stimulation are IFNγ- and complex I-dependent. Similarly, MHC class I presentation machinery is transcriptionally induced upon IFNγ stimulation (<xref ref-type="bibr" rid="bib101">Rock et al., 2016</xref>; <xref ref-type="bibr" rid="bib120">Van Rhijn et al., 2015</xref>) and the induction of molecules recognized by donor-unrestricted T cells, such as MR1 and CD1, might also require additional signals to function. The specific effects of mitochondrial respiration on the type and quality of the T cell response will depend on how these diverse antigen-presenting and co-signaling molecules are influenced by cellular metabolic state.</p><p>The observation that IFNγ signaling depends on mitochondrial respiration provides a stark contrast to the well-established glycolytic dependency of many phagocyte functions, such as TLR signaling. This metabolic dichotomy between proinflammatory TLR signals and the IFNγ response mirrors known regulatory interactions between these pathways. For example, TLR stimulation has been shown to inhibit subsequent IFNγ responses via a number of target gene-specific mechanisms (<xref ref-type="bibr" rid="bib10">Benson and Ernst, 2009</xref>; <xref ref-type="bibr" rid="bib42">Fortune et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Kincaid et al., 2007</xref>; <xref ref-type="bibr" rid="bib114">Su et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Jang and Javadov, 2020</xref>). However, TLR stimulation also results in the disassembly of the ETC (<xref ref-type="bibr" rid="bib114">Su et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Jang and Javadov, 2020</xref>), which our observations predict to inhibit STAT1 phosphorylation and IFNγ signaling at the level of the receptor complex. More generally, our work suggests that fundamental metabolic programs contribute to the integration of activation signals by APC and influence the ultimate priming of an immune response.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or <break/>reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">L3-Cas9+</td><td align="left" valign="bottom">Kiritsy and <break/>Ankley et al. <break/>(co-submitted)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary BMDMs immortalized with J2 virus were transduced with Cas9 and single cell cloned</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">EGFP-Cas9 iBMDMs</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Primary BMDMs from Jackson Stock 026179 were immortalized with J2 virus</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">sgNdufa1 EGFP-Cas9 iBMDMs</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cas9+ iBMDMs were transduced with Ndufa1 sgRNA</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">sgNdufa2 EGFP-Cas9 iBMDMs</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cas9+ iBMDMs were transduced with Ndufa2 sgRNA</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Cas9+ C57BL/6J estradiol-inducible HoxB8 progenitors</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Myeloid progenitors from Jackson stock 026179 were immortalized with HoxB8 retrovirus and maintained with 10 µM estradiol</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">sgNdufa1 C57BL/6J estradiol-inducible HoxB8 progenitors</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Cas9+ HoxB8 cells were transduced with Ndufa1 sgRNA</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Cas9+ C57BL/6J estradiol-inducible HoxB8 progenitors</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Myeloid progenitors from Jackson stock 003288 were immortalized with HoxB8 retrovirus and maintained with 10 µM estradiol</td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL6J</td><td align="left" valign="bottom">Jackson <break/>Laboratories</td><td align="left" valign="bottom">Stock 000664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C7 TCR-transgenic <break/>mice (specific for ESAT-6 antigen)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18779346/">18779346</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mice were donated to and maintained by the Behar laboratory</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">ESAT-6 peptide (MTEQQW<break/>NFAGIEAAA)</td><td align="left" valign="bottom">New England <break/>Peptide</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">sgOpti</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_85681">Addgene_ 85681</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">sgOpti with blasticidin and zeocyin selection</td><td align="left" valign="bottom">Kiritsy and <break/>Ankley <break/>et al. (co-<break/>submitted)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">sgOpti (RRID 85681) was modified with bacterial selection replaced with zeocyin and mammalian selection replaced with blasticidin</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">sgOpti with hygromycin and kanamycin selection</td><td align="left" valign="bottom">Kiritsy and <break/>Ankley et al. <break/>(co-submitted)</td><td align="left" valign="bottom"/><td align="left" valign="bottom">sgOpti (RRID 85681) was modified with bacterial selection replaced with kanamycin and mammalian selection replaced with hygromycin</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">VSVG</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_8454">Addgene_8454</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">psPax2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12260">Addgene_12260</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">MHCII-PE, clone M5/114.15.2 <break/>(rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313323">AB_313323</ext-link></td><td align="left" valign="bottom">FC (1:800)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Mouse CRISPR KO pooled library (BRIE)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_7363">Addgene_7363</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rotenone</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# R8875</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Oligomycin</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 11342</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CCCP</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 25458</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="." valign="bottom">1400W</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 81520</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">N-Acetyl cysteine</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 20261</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dimethyloxallyl glycine (DMOG)</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 71210</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">UK5099</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 16,980</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Deoxyglucose (2-DG)</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 14325</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoTEMPO hydrate</td><td align="left" valign="bottom">Cayman</td><td align="left" valign="bottom">Cat# 16621</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium azide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# S2002</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Antimycin A</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# A8674</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, <break/>drug</td><td align="left" valign="bottom">Pam3CSK4</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Cat# tlrl-pms</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, <break/>drug</td><td align="left" valign="bottom">Linezolid (LZD)</td><td align="left" valign="bottom">Gift from Clifton <break/>Barry (used here PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/32477361/">32477361</ext-link>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Purified anti-STAT1 antibody clone A15158C (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 603701; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2749867">AB_2749867</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-Stat1 Tyr701, clone 58D6 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology</td><td align="left" valign="bottom">Cat# 5375; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10860071">AB_10860071</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Purified anti-STAT1 Phospho Ser727 antibody, clone A15158B (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 686408; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2650782">AB_2650782</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Jak2 XP, clone D2E12 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology</td><td align="left" valign="bottom">Cat# 4040; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10691469">AB_10691469</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phospho-Jak2 (Tyr1007/1008) antibody (unknown)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology</td><td align="left" valign="bottom">Cat# 3771; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330403">AB_330403</ext-link></td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD119, IFNγ Rα chain antibody clone 2E2 (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 112803; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2123476">AB_2123476</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse β-actin antibody, clone C4 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz <break/>Biotechnology</td><td align="left" valign="bottom">Cat# sc-51850; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_629337">AB_629337</ext-link></td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD274-Bv421 clone 10F.9G2 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10897097">AB_10897097</ext-link></td><td align="left" valign="bottom">FC (1:400)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Zombie Aqua Fixable Viability Kit</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 423101</td><td align="left" valign="bottom">FC (1:100)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DNeasy Blood and Tissue Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 69504</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD40 APC anti-mouse CD40 antibody, clone 3/23 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 124611;RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1134081">AB_1134081</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human anti-CD54, clone HCD54 (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 322718; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2248731">AB_2248731</ext-link></td><td align="left" valign="bottom">FC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human anti-CD40 clone 5C3 (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 334307; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186060">AB_1186060</ext-link></td><td align="left" valign="bottom">FC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human anti-CD274, B7-H1, PD-L1, clone 29E (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 329713; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10901164">AB_10901164</ext-link></td><td align="left" valign="bottom">FC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Human anti-HLA-DR antibody, clone L243 (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 307657; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2572100">AB_2572100</ext-link></td><td align="left" valign="bottom">FC (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IFNγ antibody (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 505807; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315401">AB_315401</ext-link></td><td align="left" valign="bottom">FC (1:200)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Murine IL-12</td><td align="left" valign="bottom">PeproTech</td><td align="left" valign="bottom">Cat# 210-12</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human GM-CSF</td><td align="left" valign="bottom">PeproTech</td><td align="left" valign="bottom">Cat# 300-03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human IFN gamma</td><td align="left" valign="bottom">PeproTech</td><td align="left" valign="bottom">Cat# 300-02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Murine TNF</td><td align="left" valign="bottom">PeproTech</td><td align="left" valign="bottom">Cat# 315-01A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IL4 clone: 11B11 (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2750407">AB_2750407</ext-link></td><td align="left" valign="bottom">Neutralization (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit HRP (goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 31460</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse HRP (goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 31430</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">One-Step RT PCR Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat# 210215</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Luna Universal One-Step RT-qPCR Kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E3005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Trizol</td><td align="left" valign="bottom">Thermo<break/>Fisher <break/>Scientific</td><td align="left" valign="bottom">Cat# 15596026</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTiter-Glo 2.0 Cell Viability Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# G9241</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Seahorse assay media</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat# 103575-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MAGECK</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25476604/">25476604</ext-link><break/></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Interferon gamma</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 575308</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MojoSORT – Mouse CD4 Naïve T cell Isolation Kit</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 480040</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MojoSort Human CD14 Nanobeads</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# BioLegend 480093</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">IL6 ELISA-max</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 431301</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TNF ELISA-max</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 430901</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human IL1b</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human TNF-alpha DuoSet ELISA</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY210</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Greiss reagent</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">G2930</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">All oligonucleotide sequences are contained in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">All oligonucleotide sequences are contained in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>Cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco 11965118) supplemented with 10% fetal bovine serum (Sigma F4135), sodium pyruvate (Gibco 11360119), and HEPES (15630080). Primary BMDMs were generated by culturing bone marrow in the presence of media supplemented with 20% L929 supernatant for 7 days.</p><p>Immortalized macrophage cell lines in C57B/6J and Cas9-EGFP were established in using J2 retrovirus from supernatant of CREJ2 cells as previously described (<xref ref-type="bibr" rid="bib12">Blasi et al., 1989</xref>). Briefly, isolated bone marrow was cultured in the presence of media enriched with 20% L929 supernatant. On day 3, cells were transduced with virus and cultured with virus for 2 days. Over the next 8 weeks, L929 media were gradually reduced to establish growth factor independence.</p><p>Conditionally immortalized myeloid progenitor cell lines were generated by retroviral transduction using an estrogen-dependent Hoxb8 transgene as previously described (<xref ref-type="bibr" rid="bib124">Wang et al., 2006</xref>). Briefly, mononuclear cells were purified from murine bone marrow using Ficoll-Paque PLUS (GE Healthcare 17144002) and cultured in RPMI (Gibco 11875119) containing 10% fetal bovine serum (Sigma F4135), sodium pyruvate (Gibco 11360119), and HEPES (15630080), IL-6 (10 ng/mL; PeproTech #216-16), IL-3 (10 ng/mL; PeproTech #213-13), and SCF (10 ng/mL; PeproTech #250-03) for 48 hr. Non-adherent bone marrow cells from C57Bl/6J (Jax 000664), Cas9-EGFP knockin (Jax 026179), or Ifngr1 KO (Jax 003288) mice were transduced with ER-Hoxb8 retrovirus. After transduction, cells were cultured in media supplemented with supernatant from B16 cells expressing GM-CSF and 10 µM estradiol (Sigma E8875) to generate macrophage progenitor cell lines or in media supplemented with supernatant from B16 cells expressing FLT3L and 10 µM estradiol (Sigma E8875) to generate DC progenitor lines. To differentiate macrophages, progenitors were harvested and washed twice with PBS to remove residual estradiol and cultured in L929 supplemented media as above. To differentiate DCs (<xref ref-type="bibr" rid="bib98">Redecke et al., 2013</xref>), progenitors were harvested, washed 2× with PBS, and cultured in FLT3-enriched complete RPMI for 8–10 days.</p><p>Human MDMs were differentiated from mononuclear cells of healthy donors. Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Paque PLUS (GE Healthcare 17144002). CD14+ monocytes were purified using MojoSort Human CD14 Nanobeads (BioLegend 480093) according to the manufacturer’s protocol. Cells were cultured in RPMI with 10% FBS, sodium pyruvate, and HEPES and supplemented with recombinant GM-CSF (50 ng/mL, PeproTech 300-03) for 6 days. Thaws were harvested using Accutase (Gibco A1110501).</p></sec><sec id="s4-2"><title>Cell stimulations</title><p>Murine IFNγ (PeproTech 315-05) and human IFNγ (PeproTech 300-02) were used at 10 ng/mL unless indicated otherwise in the figure legends. Murine TNF (315-01A) was used at 25 ng/mL. Pam3CSK4 (Invivogen tlrl-pms) was used at 200 ng/mL.</p></sec><sec id="s4-3"><title>CRISPR screens</title><p>A clonal macrophage cell line stably expressing Cas9 (L3) was established as described elsewhere (<xref ref-type="bibr" rid="bib67">Kiritsy et al., 2021</xref>). A plasmid library of sgRNAs targeting all protein coding genes in the mouse genome (Brie Knockout library, Addgene 73633) was packaged into lentivirus using HEK293T cells. HEK293T supernatants were collected and clarified, and virus was titered by quantitative real-time PCR and colony counting after transduction of NIH3T3. L3 cells were transduced at a multiplicity of infection (MOI) of ~0.2 and selected with puromycin 48 hr after transduction (2.5 µg/mL). The library was minimally expanded to avoid skewing mutant representation and then frozen in aliquots in freezing media (90% FBS, 10% DMSO).</p><p>Two replicate screens for MHCII, CD40, and PD-L1 were performed as follows: 2e8 cells of the KO library were stimulated with IFNγ (10 ng/mL; PeproTech 315-05) for 24 hr after which cells were harvested by scraping to ensure integrity of cell surface proteins. Cell were stained with TruStain FcX anti-mouse CD16/32 (BioLegend 101319) and LIVE/DEAD Fixable Aqua (Invitrogen L34957) as per the manufacturer’s instructions. For each of the respective screens, stimulated library was stained for its respective marker with the following antibody: MHCII (APC anti-mouse I-A/I-E Antibody, clone M5/114.15.2, BioLegend 107613), CD40 (APC anti-mouse CD40 antibody, clone 3/23, BioLegend 124611), or PD-L1 (APC anti-mouse CD274 [B7-H1, PD-L1] antibody, clone 10F.9G2, BioLegend 124311). Each antibody was titrated for optimal staining using the isogenic L3 macrophage cell line. Following staining, cells were fixed in 4% paraformaldehyde. High- and low-expressing populations were isolated by FACS using a BD FACS Aria II Cell Sorter. Bin size was guided by control cells that were unstimulated and to ensure sufficient library coverage (&gt;25× unselected library, or &gt;2e6 cells per bin). Following isolation of sorted populations, paraformaldehyde crosslinks were reversed by incubation in proteinase K (Qiagen) at 55° for 6–8 hr. Subsequently, genomic DNA was isolated using DNeasy Blood and Tissue Kit (Qiagen 69504) according to the manufacturer’s instructions. Amplification of sgRNAs by PCR was performed as previously described (<xref ref-type="bibr" rid="bib35">Doench et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Joung et al., 2017</xref>) using Illumina compatible primers from IDT, and amplicons were sequenced on an Illumina NextSeq500. Sequence reads were trimmed to remove adapter sequence and adjust for staggered forward (p5) primer using Cutadapt v2.9. Raw sgRNA counts for each sorted and unsorted (input library) population were quantified using bowtie2 via MAGeCK to map reads to the sgRNA library index (no mismatch allowed); an sgRNAindex was modified to reflect genes transcribed by our macrophage cell line either basally or upon stimulation with IFNγ as previously published (<xref ref-type="bibr" rid="bib67">Kiritsy et al., 2021</xref>). Counts for sgRNAs were median normalized to account for variable sequencing depth.</p></sec><sec id="s4-4"><title>MAGeCK-MLE</title><p>We used MAGeCK-MLE to test for gene enrichment. Two separate analyses were performed in order to (1) identify regulators of the IFNγ response and (2) specific regulators of each of the screen targets. For both analyses, the baseline samples were the input libraries from each of the replicate screens in order to account for slight variabilities in library distribution for each screen. For (1), the generalized linear model was based on a design matrix that was ‘marker-blind’ and only considered the bin of origin (i.e., MHCII-low, CD40-low, PD-L1-low vs. MHCII-high, CD40-high, PD-L1-high). For (2), the design matrix was ‘marker-aware and bin-specific’ to test for marker-specific differences (i.e., MHCII-low vs. CD40-low vs. PD-L1-low); the analysis was performed separately for each bin, low- or high-expressing mutants, to identify marker-specific positive and negative regulators, respectively. For each analysis, β scores (selection coefficient) for each gene were summed across conditions to allow for simultaneous assessment of positive and negative regulators across conditions. Data are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>GSEA was performed using a ranked gene list as calculated from MAGeCK-MLE beta scores and false discovery rate (FDR). To facilitate the identification of positively and negatively enriched gene sets from the high- and low-expressing populations, the positive (‘pos | beta’) and negative (‘neg | beta’) beta scores for each gene were summed as described above (‘beta_sum’). To generate a ranked gene list for GSEA, we employed Stouffer’s method to sum positive (‘pos | z’) and negative (‘neg | z’) selection z-scores, which were used to recalculate p-values (‘p_sum’) as has been previously described (<xref ref-type="bibr" rid="bib19">Brown, 1975</xref>; <xref ref-type="bibr" rid="bib60">Jia et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Bodapati et al., 2020</xref>). Using these summative metrics, we calculated a gene score as log10(p_sum) * (beta_sum). Genes were ranked in descending order, and GSEA was performed with standard settings including ‘weighted’ enrichment statistic and ‘meandiv’ normalization mode. Analysis was inclusive of gene sets comprising 10–500 genes that were compiled and made available online by the Bader lab (<xref ref-type="bibr" rid="bib84">Merico et al., 2010</xref>; <xref ref-type="bibr" rid="bib99">Reimand et al., 2019</xref>).</p></sec><sec id="s4-5"><title>Plasmids and sgRNA cloning</title><p>Lentivirus was generated using HEK293T cells with packaging vector psPAX2 (Addgene #12260) and envelope plasmid encoding VSV-G. Transfections used TransIT-293 (MirusBio MIR 2704) and plasmid ratios were calculated according to the manufacturer’s instructions. For the generation of retrovirus, pCL-Eco in place of separate packaging and envelope plasmid was used. Retrovirus encoding the ER-Hoxb8 transgene was kindly provided by David Sykes. sgOpti was a gift from Eric Lander and David Sabatini (Addgene plasmid #85681; <xref ref-type="bibr" rid="bib44">Fulco et al., 2016</xref>). Individual sgRNAs were cloned as previously described. Briefly, annealed oligos containing the sgRNA targeting sequence were phosphorylated and cloned into a dephosphorylated and BsmBI (New England Biolabs) digested SgOpti (Addgene #85681), which contains a modified sgRNA scaffold for improved sgRNA-Cas9 complexing. Use of sgOpti derivatives for delivery of multiple sgRNAs was performed as detailed elsewhere (<xref ref-type="bibr" rid="bib67">Kiritsy et al., 2021</xref>). The sgRNA targeting sequences used for cloning were as follows:</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Name/target</th><th align="left" valign="top">sgRNA sequence</th></tr></thead><tbody><tr><td align="left" valign="top">sgIfngr1_1</td><td align="left" valign="top"><named-content content-type="sequence">TATGTGGAGCATAACCGGAG</named-content></td></tr><tr><td align="left" valign="top">sgIfngr1_2</td><td align="left" valign="top"><named-content content-type="sequence">GGTATTCCCAGCATACGACA</named-content></td></tr><tr><td align="left" valign="top">sgIrf1_1</td><td align="left" valign="top"><named-content content-type="sequence">CTGTAGGTTATACAGATCAG</named-content></td></tr><tr><td align="left" valign="top">sgIrf1_2</td><td align="left" valign="top"><named-content content-type="sequence">CGGAGCTGGGCCATTCACAC</named-content></td></tr><tr><td align="left" valign="top">sgPtpn2_1</td><td align="left" valign="top"><named-content content-type="sequence">AAGAAGTTACATCTTAACAC</named-content></td></tr><tr><td align="left" valign="top">sgPtpn2_2</td><td align="left" valign="top"><named-content content-type="sequence">TGCAGTGATCCATTGCAGTG</named-content></td></tr><tr><td align="left" valign="top">sgNdufa1_1</td><td align="left" valign="top"><named-content content-type="sequence">TGTACGCAGTGGACACCCCG</named-content></td></tr><tr><td align="left" valign="top">sgNdufa1_2</td><td align="left" valign="top"><named-content content-type="sequence">CGCGTTCCATCAGATACCAC</named-content></td></tr><tr><td align="left" valign="top">sgNdufa2_1</td><td align="left" valign="top"><named-content content-type="sequence">GCAGGGATTTCATCGTGCAA</named-content></td></tr><tr><td align="left" valign="top">sgNdufa2_2</td><td align="left" valign="top"><named-content content-type="sequence">ATTCGCGGATCAGAATGGGC</named-content></td></tr><tr><td align="left" valign="top">sgStat1_1</td><td align="left" valign="top"><named-content content-type="sequence">GGATAGACGCCCAGCCACTG</named-content></td></tr><tr><td align="left" valign="top">sgStat1_2</td><td align="left" valign="top"><named-content content-type="sequence">TGTGATGTTAGATAAACAGA</named-content></td></tr><tr><td align="left" valign="top">sgOstc_1</td><td align="left" valign="top"><named-content content-type="sequence">GCGTACACCGTCATAGCCGA</named-content></td></tr><tr><td align="left" valign="top">sgOstc_2</td><td align="left" valign="top"><named-content content-type="sequence">TCTTACTTCCTCATTACCGG</named-content></td></tr><tr><td align="left" valign="top">sgCnbp_1</td><td align="left" valign="top"><named-content content-type="sequence">AGGTAAAACCACCTCTGCCG</named-content></td></tr><tr><td align="left" valign="top">sgCnbp_2</td><td align="left" valign="top"><named-content content-type="sequence">GTTGAAGCCTGCTATAACTG</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4-6"><title>Flow cytometry</title><p>Cells were harvested at the indicated times post-IFNγ stimulation by scrapping to ensure intact surface proteins. Cells were pelleted and washed with PBS before staining with TruStain FcX anti-mouse CD16/32 (BioLegend 101319) or TruStain FcX anti-human (BioLegend 422301) and LIVE/DEAD Fixable Aqua (Invitrogen L34957) as per the manufacturer’s instructions. The following antibodies were used as indicated in the figure legends:</p><list list-type="bullet"><list-item><p>APC-Fire750 anti-mouse I-A/I-E antibody, clone M5/114.15.2, BioLegend 107651</p></list-item><list-item><p>PE anti-mouse CD40 antibody, clone 3/23, BioLegend 124609</p></list-item><list-item><p>Brilliant Violet 421 anti-mouse CD274 (B7-H1, PD-L1) antibody, clone 10F.9G2, BioLegend 124315</p></list-item><list-item><p>Alexa Fluor 647 anti-human CD54 antibody, clone HCD54, BioLegend 322718</p></list-item><list-item><p>PE anti-human CD40 antibody, clone 5C3, BioLegend 334307</p></list-item><list-item><p>Brilliant Violet 421 anti-human CD274 (B7-H1, PD-L1) antibody, clone 29E.2A3, BioLegend 329713</p></list-item><list-item><p>APC/Fire 750 anti-human HLA-DR antibody, clone L243, BioLegend 307657</p></list-item></list><p>For intracellular cytokine staining, cells were treated with brefeldin A (BioLegend 420601) for 5 hr before harvesting. Following staining and fixation, cells were permeabilized (BioLegend 421002) and stained according to the manufacturer’s protocol using the following antibodies: PE anti-mouse IFNγ antibody, BioLegend 505807.</p><p>Surface protein expression was analyzed on either a MacsQuant Analyzer or Cytek Aurora. All flow cytometry analyses were done in FlowJo V10 (TreeStar).</p></sec><sec id="s4-7"><title>Chemical inhibitors</title><p>All chemical inhibitors were used for the duration of cell stimulation unless otherwise stated. Rotenone (Sigma R8875) was resuspended in DMSO and used at 10 µM unless indicated otherwise in the figure legends. Oligomycin (Cayman 11342) was resuspended in DMSO and used at 2.5 µM unless indicated otherwise. CCCP (Cayman 25458) was resuspended in DMSO and used at 1.5 µM unless indicated otherwise. 1400W hydrochloride (Cayman 81520) was resuspended in culture media, filter sterilized, and used immediately at 25 µM unless indicated otherwise. NAC (Cayman 20261) was resuspended in culture media, filter sterilized, and used immediately at 10 mM. DMOG (Cayman 71210) was resuspended in DMSO and used at 200 µM. UK5099 (Cayman 16980) was resuspended in DMSO and used at 20 µM. 2-Deoxy-D-glucose (2DG, Cayman 14325) was resuspended in culture media, filter sterilized, and used at 1 mM or at the indicated concentrations immediately. MitoTEMPO hydrate (Cayman 16621) was resuspended in DMSO and used at the indicated concentrations. Antimycin A (Sigma A8674) and sodium azide (Sigma S2002) were resuspended in DMSO, filter sterilized, and used at indicated concentrations.</p><p>For experiments that used defined minimal media with carbon supplementation, D-galactose, sodium pyruvate, and D-glucose were used at 10 mM in DMEM without any carbon (Gibco A1443001). For establishment of macrophage cell line with diminished mitochondrial mass, cells were continuously cultured in LZD (kind gift from Clifton Barry) for 4 weeks at 50 μg/mL or DMSO control. Both LZD-conditioned and DMSO control lines were supplemented with uridine at 50 μg/mL. Prior to experimentation, cells were washed with PBS and cultured without LZD for at least 12 hr.</p></sec><sec id="s4-8"><title>ELISA and nitric oxide quantification</title><p>The following kits were purchased from R&amp;D Systems or BioLegend for quantifying protein for cell supernatants:</p><list list-type="bullet"><list-item><p>Mouse IL-6 DuoSet ELISA (DY406) or BioLegend ELISA-max (431301)</p></list-item><list-item><p>Mouse TNF-alpha DuoSet ELISA (DY410) or BioLegend ELISA-max (430901)</p></list-item><list-item><p>Mouse IFN-gamma DuoSet ELISA (DY485)</p></list-item><list-item><p>Human IL-1 beta/IL-1F2 DuoSet ELISA (DY201)</p></list-item><list-item><p>Human TNF-alpha DuoSet ELISA (DY210)</p></list-item></list><p>Nitric oxide was quantified from cell supernatants using the Griess Reagent System according to the manufacturer’s instructions (Promega G2930). For these experiments, cell culture media without phenol red (Gibco A1443001 or Gibco 31053028) were used.</p></sec><sec id="s4-9"><title>RNA isolation and quantitative real-time PCR</title><p>To isolate RNA, cells were lysed in TRIzol (15596026) according to the manufacturer’s instructions. Chloroform was added to lysis at a ratio of 200 µL chloroform per 1 mL TRIzol and centrifuged at 12,000 × g for 20 min at 4°C. The aqueous layer was separated and added to equal volume of 100% ethanol. RNA was isolated using the Zymo Research Direct-zol RNA extraction kit. Quantity and purity of the RNA were checked using a NanoDrop and diluted to 5 ng/µL in nuclease-free water before use. Quantitative real-time PCR was performed using NEB Luna Universal One-Step RT-qPCR Kit (E3005) or the Quantitect SYBR green RT-PCR kit (204243) according to the manufacturer’s protocol and run on a Viia7 thermocycler or StepOne Plus Theromocycler. Relative gene expression was determined with ddCT method with β-actin transcript as the reference.</p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Primer</th><th align="left" valign="top">Sequence</th></tr></thead><tbody><tr><td align="left" valign="top">RT_Actb-1F</td><td align="left" valign="top">GGCTGTATTCCCCTCCATCG</td></tr><tr><td align="left" valign="top">RT_Actb-1R</td><td align="left" valign="top">CCAGTTGGTAACAATGCCATGT</td></tr><tr><td align="left" valign="top">RT_Cd274-1F</td><td align="left" valign="top">GCTCCAAAGGACTTGTACGTG</td></tr><tr><td align="left" valign="top">RT_Cd274-1R</td><td align="left" valign="top">TGATCTGAAGGGCAGCATTTC</td></tr><tr><td align="left" valign="top">RT-Ciita-1F</td><td align="left" valign="top">AGACCTGGATCGTCTCGT</td></tr><tr><td align="left" valign="top">RT-Ciita-1R</td><td align="left" valign="top">AGTGCATGATTTGAGCGTCTC</td></tr><tr><td align="left" valign="top">RT-Gapdh-1F</td><td align="left" valign="top">TGGCCTTCCGTGTTCCTAC</td></tr><tr><td align="left" valign="top">RT-Gapdh-1R</td><td align="left" valign="top">GAGTTGCTGTTGAAGTCGCA</td></tr></tbody></table></table-wrap></sec><sec id="s4-10"><title>Quantification of mitochondrial genomes</title><p>Genomic DNA was isolated from cell pellets using the DNeasy Blood and Tissue Kit (Qiagen 69504). Quantitative PCR was run using NEB Luna Universal One-Step RT-qPCR without the RT enzyme mix and run on a Viia7 thermocycler. Relative quantification of mitochondrial genomes was determined by measuring the relative abundance of mitochondrially encoded gene Nd1 to the abundance of nuclear encoded Hk2 as has been described elsewhere (<xref ref-type="bibr" rid="bib40">Field et al., 2020</xref>). All primers are detailed as follows:</p><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Name/target</th><th align="left" valign="top">Sequence</th></tr></thead><tbody><tr><td align="left" valign="top">Mm-Nd1-1F</td><td align="left" valign="top">CTAGCAGAAACAAACCGGGC</td></tr><tr><td align="left" valign="top">Mm-Nd1-1R</td><td align="left" valign="top">CCGGCTGCGTATTCTACGTT</td></tr><tr><td align="left" valign="top">Mm-Hk2-1F</td><td align="left" valign="top">GCCAGCCTCTCCTGATTTTAGTGT</td></tr><tr><td align="left" valign="top">Mm-Hk2-1R</td><td align="left" valign="top">GGGAACACAAAAGACCTCTTCTGG</td></tr></tbody></table></table-wrap></sec><sec id="s4-11"><title>Immunoblot</title><p>At the indicated times following stimulation, cells were washed with PBS once and lysed in ice using the following buffer: 1% Triton X-100, 150 mM NaCl, 5 mM KCl, 2 mM MgCl<sub>2</sub>, 1 mM EDTA, 0.1% SDS, 0.5% DOC, 25 mM Tris-HCl, pH 7.4, with protease and phosphatase inhibitor (Sigma #11873580001 and Sigma P5726). Lysates were further homogenized using a 25 g needle and cleared by centrifugation before quantification (Pierce BCA Protein Assay Kit, 23225). Parallel blots were run with the same samples, 15 µg per well. The following antibodies were used according to the manufacturer’s instructions:</p><list list-type="bullet"><list-item><p>Purified anti-STAT1 antibody, BioLegend, clone A15158C</p></list-item><list-item><p>Purified anti-STAT1 phospho (Ser727) antibody, BioLegend, clone A15158B</p></list-item><list-item><p>Phospho-Stat1 (Tyr701) rabbit mAb, Cell Signaling Technology, clone 58D6</p></list-item><list-item><p>Jak2 XP rabbit mAb, Cell Signaling Technology, clone D2E12</p></list-item><list-item><p>Phospho-Jak2 (Tyr1007/1008) antibody, Cell Signaling Technology, #3771S</p></list-item><list-item><p>Anti-mouse β-actin antibody, Santa Cruz Biotechnology, clone C4</p></list-item><list-item><p>Biotin anti-mouse CD119 (IFN-γ Rα chain) antibody, BioLegend, clone 2E2</p></list-item><list-item><p>Goat anti-rabbit IgG (H + L) secondary antibody, HRP, Invitrogen 31460</p></list-item><list-item><p>Goat anti-mouse IgG (H + L) secondary antibody, HRP, Invitrogen 31430</p></list-item><list-item><p>HRP-conjugated streptavidin, Thermo Scientific N100.</p></list-item></list></sec><sec id="s4-12"><title>Bioenergetics assays</title><p>Relative glycolytic and respiratory capacities were determined as has previously been demonstrated (<xref ref-type="bibr" rid="bib55">Horlbeck et al., 2018</xref>). Briefly, cellular ATP levels were determined using CellTiter-Glo 2.0 Cell Viability Assay (Promega G9241) according to the manufacturer’s protocol. Cells were grown in the conditions indicated in the figure legends for 4 hr unless stated otherwise. ATP levels were normalized according to the figure legends.</p></sec><sec id="s4-13"><title>Seahorse metabolic rate assays with BMDMs</title><p>Wild-type (C57Bl/6J) BMDMs were seeded in a Seahorse cell culture plate at 10<sup>5</sup> cells per well and stimulated for 24 hr with recombinant murine IFNγ (10 ng/mL) or Pam3CSK4 (200 ng/mL). Cellular oxidative phosphorylation and glycolysis were measured using the Seahorse Bioscience Extracellular Flux Analyzer (XFe96, Seahorse Bioscience Inc, North Billerica, MA) by measuring OCR (indicative of respiration) and ECAR (indicative of glycolysis) in real time according to the manufacturer’s protocol. Prior to measurements, culture media were removed and replaced with 180  µL pH ready Seahorse Assay Media (Agilent; Catal#103575-100) and incubated in the absence of CO<sub>2</sub> for 1 hr in the BioTek Cytation1 instrument during which time pre-assay brightfield images were collected. Basal levels of OCR and ECAR were recorded, then OCR and ECAR levels following injection of compounds that inhibit the mitochondrial ETC, or ATP synthesis were monitored. As per the manufacturer’s protocol for the Mito Stress Test, assay cells were sequentially treated with oligomycin (2  µM), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5  µM), and rotenone + antimycin A (0.5  µM). OCR and ECAR were then measured in a standard 6 min cycle of mix (2 min), wait (2 min), and measure (2 min). All OCR and ECAR values were normalized following the Seahorse normalization protocol. Briefly after, the assay cells were stained with 2 μg/mL Hoechst 33342 (Thermo Fisher Scientific) for 30 min while performing post-assay brightfield imaging. Cells were then imaged and counted using the BioTek Cytation1. Cell counts were calculated by Cell Imaging software (Agilent) and imported into Wave (Agilent) using the normalization function.</p></sec><sec id="s4-14"><title>T cell activation assay</title><p>We used a previously established co-culture system to assess antigen presentation to Ag-specific T cells. Briefly, C7 CD4+ T cells were isolated from transgenic C7 mice, respectively, and stimulated in vitro with irradiated splenocytes pulsed with the ESAT-61-15 peptide in complete media (RPMI with 10% FBS) containing IL-2 and IL-7. After the initial stimulation, the T cells were split every 2 days for 3–4 divisions and rested for 2–3 weeks. After the initial stimulation, the cells were cultured in complete media containing IL-2 and IL-7. The following synthetic peptide epitopes were used as antigens from New England Peptide (Gardener, MA): ESAT-61-15 (MTEQQWNFAGIEAAA).</p><p>For use in co-culture assay, T cells were added to peptide-pulsed macrophages as described in the figure legends at an effector to target ratio of 1:1. Following 1 hr of co-culture, brefeldin A was added for 5 hr before assessing intracellular cytokine production by ICS.</p></sec><sec id="s4-15"><title>Quantification of subunit effects on N-module</title><p>We used publicly available proteomics data in which the protein abundance of all complex I subunit was measured when each subunit was genetically deleted (<xref ref-type="bibr" rid="bib112">Stroud et al., 2016</xref>). As determined empirically by the authors, the N-module components included NDUFA1, NDUFA2, NDUFS1, NDUFV2, NDUFA6, NDUFS6, NDUFA7, NDUFS4, and NDUFV3. The relative effect of each subunit (using a KO of that subunit) on N-module protein stability was calculated as the sum of the median log2 ratio of each of the abovementioned subunits minus the median log2 ratio of itself (since it is knocked out).</p></sec><sec id="s4-16"><title>Statistical analysis, replicates, grouping, and figures</title><p>Statistical analysis was done using Prism version 7 (GraphPad) as indicated in the figure legends. Data are presented, unless indicated otherwise, as the mean ± standard deviation. Throughout the article, no explicit power analysis was used, but group size was based on previous studies using similar approaches. Throughout the article, biological replicate refers to independent wells or experiments processed at similar times. For RT-PCR experiments, technical replicates were used and are defined as repeat measures from the same well. Throughout the article, groups were assigned based on genotypes and blinding was not used throughout. Independent personnel completed several key figures to ensure robustness. Figures were created in Prism V8, R (version 3.6.2). MAGeCK-MLE was used as part of MAGeCK-FLUTE package v1.8.0 or was created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link>.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con5"><p>Methodology, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Funding acquisition, Supervision, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Validation, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All human blood samples were donated following informed consent and approved under IRB protocol I-375-19.</p></fn><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (PROTO201800057) of Michigan State University and (Protocol# 1649) of the University of Massachusetts Medical School.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Oligonucleotides used in this study.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-65109-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-65109-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Raw sequencing data in FASTQ and processed formats is available for download from NCBI Gene Expression Omnibus (GEO) under accession number GSE162463.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kiritsy</surname><given-names>MC</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name><name><surname>Olive</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Mitochondrial respiration contributes to the interferon gamma response in antigen presenting cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162463">GSE162463</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all the members of the Sassetti, Behar, and Olive labs for critical feedback and input throughout the project. A special thanks to Megan K Proulx, Mario Meza Segura, and the donors for their assistance and expertise to the human macrophage derivation We thank the flow cytometry core at UMMS for their help in all experiments requiring flow cytometry. This work was supported by startup funding to AJO provided by Michigan State University, support from the Arnold O Beckman Postdoctoral fellowship to AJO, and grants from the NIH (AI146504, AI132130), DOD (W81XWH2010147), and USDA (NIFA HATCH 1019371).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dendritic cells giveth and taketh away</article-title><source>Nature Immunology</source><volume>6</volume><fpage>227</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/ni0305-227</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcaïs</surname><given-names>A</given-names></name><name><surname>Fieschi</surname><given-names>C</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Tuberculosis in children and adults: two distinct genetic diseases</article-title><source>The Journal of Experimental Medicine</source><volume>202</volume><fpage>1617</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1084/jem.20052302</pub-id><pub-id pub-id-type="pmid">16365144</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>MR</given-names></name><name><surname>Armitage</surname><given-names>RJ</given-names></name><name><surname>Tough</surname><given-names>TW</given-names></name><name><surname>Strockbine</surname><given-names>L</given-names></name><name><surname>Fanslow</surname><given-names>WC</given-names></name><name><surname>Spriggs</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40</article-title><source>The Journal of Experimental Medicine</source><volume>178</volume><fpage>669</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1084/jem.178.2.669</pub-id><pub-id pub-id-type="pmid">7688031</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attanasio</surname><given-names>J</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease</article-title><source>Immunity</source><volume>44</volume><fpage>1052</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.04.022</pub-id><pub-id pub-id-type="pmid">27192569</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baardman</surname><given-names>J</given-names></name><name><surname>Verberk</surname><given-names>SGS</given-names></name><name><surname>Prange</surname><given-names>KHM</given-names></name><name><surname>van Weeghel</surname><given-names>M</given-names></name><name><surname>van der Velden</surname><given-names>S</given-names></name><name><surname>Ryan</surname><given-names>DG</given-names></name><name><surname>Wüst</surname><given-names>RCI</given-names></name><name><surname>Neele</surname><given-names>AE</given-names></name><name><surname>Speijer</surname><given-names>D</given-names></name><name><surname>Denis</surname><given-names>SW</given-names></name><name><surname>Witte</surname><given-names>ME</given-names></name><name><surname>Houtkooper</surname><given-names>RH</given-names></name><name><surname>O’neill</surname><given-names>LA</given-names></name><name><surname>Knatko</surname><given-names>EV</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><name><surname>Lutgens</surname><given-names>E</given-names></name><name><surname>de Winther</surname><given-names>MPJ</given-names></name><name><surname>Van den Bossche</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia</article-title><source>Cell Reports</source><volume>25</volume><fpage>2044</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.092</pub-id><pub-id pub-id-type="pmid">30463003</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balic</surname><given-names>JJ</given-names></name><name><surname>Albargy</surname><given-names>H</given-names></name><name><surname>Luu</surname><given-names>K</given-names></name><name><surname>Kirby</surname><given-names>FJ</given-names></name><name><surname>Jayasekara</surname><given-names>WSN</given-names></name><name><surname>Mansell</surname><given-names>F</given-names></name><name><surname>Garama</surname><given-names>DJ</given-names></name><name><surname>Nardo</surname><given-names>DD</given-names></name><name><surname>Baschuk</surname><given-names>N</given-names></name><name><surname>Louis</surname><given-names>C</given-names></name><name><surname>Humphries</surname><given-names>F</given-names></name><name><surname>Fitzgerald</surname><given-names>K</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Gough</surname><given-names>DJ</given-names></name><name><surname>Mansell</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>metabolic reprogramming and IL-1 β expression</article-title><source>Nature Communications</source><volume>11</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41467-020-17669-5</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baradaran</surname><given-names>R</given-names></name><name><surname>Berrisford</surname><given-names>JM</given-names></name><name><surname>Minhas</surname><given-names>GS</given-names></name><name><surname>Sazanov</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Crystal structure of the entire respiratory complex I</article-title><source>Nature</source><volume>494</volume><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/nature11871</pub-id><pub-id pub-id-type="pmid">23417064</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrientos</surname><given-names>A</given-names></name><name><surname>Moraes</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Titrating the effects of mitochondrial complex I impairment in the cell physiology</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>16188</fpage><lpage>16197</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.23.16188</pub-id><pub-id pub-id-type="pmid">10347173</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>GL</given-names></name><name><surname>Paterson</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of tumor growth by IFN-gamma in cancer immunotherapy</article-title><source>Immunologic Research</source><volume>24</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1385/IR:24:2:201</pub-id><pub-id pub-id-type="pmid">11594457</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>SA</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TLR2-dependent inhibition of macrophage responses to IFN-gamma is mediated by distinct, gene-specific mechanisms</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e6329</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006329</pub-id><pub-id pub-id-type="pmid">19629181</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>MY</given-names></name><name><surname>Solanki</surname><given-names>HS</given-names></name><name><surname>Advani</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>AA</given-names></name><name><surname>Keshava Prasad</surname><given-names>TS</given-names></name><name><surname>Gowda</surname><given-names>H</given-names></name><name><surname>Thiyagarajan</surname><given-names>S</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive network map of interferon gamma signaling</article-title><source>Journal of Cell Communication and Signaling</source><volume>12</volume><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s12079-018-0486-y</pub-id><pub-id pub-id-type="pmid">30191398</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasi</surname><given-names>E</given-names></name><name><surname>Radzioch</surname><given-names>D</given-names></name><name><surname>Merletti</surname><given-names>L</given-names></name><name><surname>Varesio</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Generation of macrophage cell line from fresh bone marrow cells with a myc/raf recombinant retrovirus</article-title><source>Cancer Biochemistry Biophysics</source><volume>10</volume><fpage>303</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">2695237</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blouin</surname><given-names>CM</given-names></name><name><surname>Lamaze</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interferon gamma receptor: the beginning of the journey</article-title><source>Frontiers in Immunology</source><volume>4</volume><elocation-id>267</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00267</pub-id><pub-id pub-id-type="pmid">24027571</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodapati</surname><given-names>S</given-names></name><name><surname>Daley</surname><given-names>TP</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A benchmark of algorithms for the analysis of pooled CRISPR screens</article-title><source>Genome Biology</source><volume>21</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-020-01972-x</pub-id><pub-id pub-id-type="pmid">32151271</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>Byun</surname><given-names>M</given-names></name><name><surname>Durfee</surname><given-names>LA</given-names></name><name><surname>Abhyankar</surname><given-names>A</given-names></name><name><surname>Sanal</surname><given-names>O</given-names></name><name><surname>Mansouri</surname><given-names>D</given-names></name><name><surname>Salem</surname><given-names>S</given-names></name><name><surname>Radovanovic</surname><given-names>I</given-names></name><name><surname>Grant</surname><given-names>AV</given-names></name><name><surname>Adimi</surname><given-names>P</given-names></name><name><surname>Mansouri</surname><given-names>N</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Bryant</surname><given-names>VL</given-names></name><name><surname>Kong</surname><given-names>XF</given-names></name><name><surname>Kreins</surname><given-names>A</given-names></name><name><surname>Velez</surname><given-names>MM</given-names></name><name><surname>Boisson</surname><given-names>B</given-names></name><name><surname>Khalilzadeh</surname><given-names>S</given-names></name><name><surname>Ozcelik</surname><given-names>U</given-names></name><name><surname>Darazam</surname><given-names>IA</given-names></name><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Al-Muhsen</surname><given-names>S</given-names></name><name><surname>Behr</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>G</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name><name><surname>Huibregtse</surname><given-names>JM</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mycobacterial Disease and Impaired IFN-γ Immunity in Humans with Inherited ISG15 Deficiency</article-title><source>Science</source><volume>337</volume><fpage>1684</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1126/science.1224026</pub-id><pub-id pub-id-type="pmid">22859821</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bousoik</surname><given-names>E</given-names></name><name><surname>Montazeri Aliabadi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway</article-title><source>Frontiers in Oncology</source><volume>8</volume><elocation-id>287</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00287</pub-id><pub-id pub-id-type="pmid">30109213</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>MD</given-names></name><name><surname>Nicholls</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Assessing mitochondrial dysfunction in cells</article-title><source>The Biochemical Journal</source><volume>435</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1042/BJ20110162</pub-id><pub-id pub-id-type="pmid">21726199</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braverman</surname><given-names>J</given-names></name><name><surname>Stanley</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nitric Oxide Modulates Macrophage Responses to Mycobacterium tuberculosis Infection through Activation of HIF-1α and Repression of NF-κB</article-title><source>Journal of Immunology</source><volume>199</volume><fpage>1805</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1700515</pub-id><pub-id pub-id-type="pmid">28754681</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>400: A Method for Combining Non-Independent, One-Sided Tests of Significance</article-title><source>Biometrics</source><volume>31</volume><elocation-id>987</elocation-id><pub-id pub-id-type="doi">10.2307/2529826</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Dorfman</surname><given-names>DM</given-names></name><name><surname>Ma</surname><given-names>F-R</given-names></name><name><surname>Sullivan</surname><given-names>EL</given-names></name><name><surname>Munoz</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Greenfield</surname><given-names>EA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production</article-title><source>Journal of Immunology</source><volume>170</volume><fpage>1257</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.3.1257</pub-id><pub-id pub-id-type="pmid">12538684</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buck</surname><given-names>MD</given-names></name><name><surname>O’Sullivan</surname><given-names>D</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>T cell metabolism drives immunity</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>1345</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1084/jem.20151159</pub-id><pub-id pub-id-type="pmid">26261266</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burr</surname><given-names>ML</given-names></name><name><surname>Sparbier</surname><given-names>CE</given-names></name><name><surname>Chan</surname><given-names>Y-C</given-names></name><name><surname>Williamson</surname><given-names>JC</given-names></name><name><surname>Woods</surname><given-names>K</given-names></name><name><surname>Beavis</surname><given-names>PA</given-names></name><name><surname>Lam</surname><given-names>EYN</given-names></name><name><surname>Henderson</surname><given-names>MA</given-names></name><name><surname>Bell</surname><given-names>CC</given-names></name><name><surname>Stolzenburg</surname><given-names>S</given-names></name><name><surname>Gilan</surname><given-names>O</given-names></name><name><surname>Bloor</surname><given-names>S</given-names></name><name><surname>Noori</surname><given-names>T</given-names></name><name><surname>Morgens</surname><given-names>DW</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Neeson</surname><given-names>PJ</given-names></name><name><surname>Behren</surname><given-names>A</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name><name><surname>Dawson</surname><given-names>S-J</given-names></name><name><surname>Voskoboinik</surname><given-names>I</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Lehner</surname><given-names>PJ</given-names></name><name><surname>Dawson</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CMTM6 maintains the expression of PD-L1 and regulates anti-Tumour immunity</article-title><source>Nature</source><volume>549</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature23643</pub-id><pub-id pub-id-type="pmid">28813417</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bustamante</surname><given-names>E</given-names></name><name><surname>Morris</surname><given-names>HP</given-names></name><name><surname>Pedersen</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="1978">1978</year><chapter-title>Hexokinase</chapter-title><person-group person-group-type="editor"><name><surname>Bustamante</surname><given-names>E</given-names></name></person-group><source>The Direct Link between Mitochondrial and Glycolytic Reactions in Rapidly Growing Cancer Cells</source><publisher-loc>Boston, MA</publisher-loc><publisher-name>Springer</publisher-name><fpage>363</fpage><lpage>380</lpage></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity</article-title><source>Seminars in Immunology</source><volume>26</volume><fpage>454</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2014.09.008</pub-id><pub-id pub-id-type="pmid">25453225</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buxadé</surname><given-names>M</given-names></name><name><surname>Huerga Encabo</surname><given-names>H</given-names></name><name><surname>Riera-Borrull</surname><given-names>M</given-names></name><name><surname>Quintana-Gallardo</surname><given-names>L</given-names></name><name><surname>López-Cotarelo</surname><given-names>P</given-names></name><name><surname>Tellechea</surname><given-names>M</given-names></name><name><surname>Martínez-Martínez</surname><given-names>S</given-names></name><name><surname>Redondo</surname><given-names>JM</given-names></name><name><surname>Martín-Caballero</surname><given-names>J</given-names></name><name><surname>Flores</surname><given-names>JM</given-names></name><name><surname>Bosch</surname><given-names>E</given-names></name><name><surname>Rodríguez-Fernández</surname><given-names>JL</given-names></name><name><surname>Aramburu</surname><given-names>J</given-names></name><name><surname>López-Rodríguez</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2901</fpage><lpage>2918</lpage><pub-id pub-id-type="doi">10.1084/jem.20180314</pub-id><pub-id pub-id-type="pmid">30327417</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>AM</given-names></name><name><surname>Castoldi</surname><given-names>A</given-names></name><name><surname>Sanin</surname><given-names>DE</given-names></name><name><surname>Flachsmann</surname><given-names>LJ</given-names></name><name><surname>Field</surname><given-names>CS</given-names></name><name><surname>Puleston</surname><given-names>DJ</given-names></name><name><surname>Kyle</surname><given-names>RL</given-names></name><name><surname>Patterson</surname><given-names>AE</given-names></name><name><surname>Hässler</surname><given-names>F</given-names></name><name><surname>Buescher</surname><given-names>JM</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inflammatory macrophage dependence on NAD+ salvage is a consequence of reactive oxygen species-mediated DNA damage</article-title><source>Nature Immunology</source><volume>20</volume><fpage>420</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0336-y</pub-id><pub-id pub-id-type="pmid">30858618</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>FRG</given-names></name><name><surname>Lepelley</surname><given-names>A</given-names></name><name><surname>Seeley</surname><given-names>JJ</given-names></name><name><surname>Hayden</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An Essential Role for ECSIT in Mitochondrial Complex I Assembly and Mitophagy in Macrophages</article-title><source>Cell Reports</source><volume>22</volume><fpage>2654</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.02.051</pub-id><pub-id pub-id-type="pmid">29514094</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>F</given-names></name><name><surname>Cardoso</surname><given-names>AP</given-names></name><name><surname>Gonçalves</surname><given-names>RM</given-names></name><name><surname>Serre</surname><given-names>K</given-names></name><name><surname>Oliveira</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>847</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00847</pub-id><pub-id pub-id-type="pmid">29780381</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapoval</surname><given-names>AI</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>JS</given-names></name><name><surname>Wilcox</surname><given-names>RA</given-names></name><name><surname>Flies</surname><given-names>DB</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>H</given-names></name><name><surname>Sica</surname><given-names>GL</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Tamada</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production</article-title><source>Nature Immunology</source><volume>2</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/85339</pub-id><pub-id pub-id-type="pmid">11224528</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway</article-title><source>Immunobiology</source><volume>217</volume><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2011.10.016</pub-id><pub-id pub-id-type="pmid">22204817</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SC</given-names></name><name><surname>Quintin</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>RA</given-names></name><name><surname>Shepardson</surname><given-names>KM</given-names></name><name><surname>Saeed</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Martens</surname><given-names>JHA</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Aghajanirefah</surname><given-names>A</given-names></name><name><surname>Manjeri</surname><given-names>GR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ifrim</surname><given-names>DC</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van der Veer</surname><given-names>B</given-names></name><name><surname>Deen</surname><given-names>PMT</given-names></name><name><surname>Logie</surname><given-names>C</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name><name><surname>Willems</surname><given-names>P</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>van der Meer</surname><given-names>JWM</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><volume>345</volume><elocation-id>1250684</elocation-id><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>MA</given-names></name><name><surname>de Carné Trécesson</surname><given-names>S</given-names></name><name><surname>Rana</surname><given-names>S</given-names></name><name><surname>Zecchin</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Molina-Arcas</surname><given-names>M</given-names></name><name><surname>East</surname><given-names>P</given-names></name><name><surname>Spencer-Dene</surname><given-names>B</given-names></name><name><surname>Nye</surname><given-names>E</given-names></name><name><surname>Barnouin</surname><given-names>K</given-names></name><name><surname>Snijders</surname><given-names>AP</given-names></name><name><surname>Lai</surname><given-names>WS</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA</article-title><source>Immunity</source><volume>47</volume><fpage>1083</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.11.016</pub-id><pub-id pub-id-type="pmid">29246442</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cramer</surname><given-names>T</given-names></name><name><surname>Yamanishi</surname><given-names>Y</given-names></name><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name><name><surname>Pawlinski</surname><given-names>R</given-names></name><name><surname>Mackman</surname><given-names>N</given-names></name><name><surname>Haase</surname><given-names>VH</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Corr</surname><given-names>M</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>HIF-1alpha is essential for myeloid cell-mediated inflammation</article-title><source>Cell</source><volume>112</volume><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00154-5</pub-id><pub-id pub-id-type="pmid">12628185</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vriese</surname><given-names>AS</given-names></name><name><surname>Coster</surname><given-names>RV</given-names></name><name><surname>Smet</surname><given-names>J</given-names></name><name><surname>Seneca</surname><given-names>S</given-names></name><name><surname>Lovering</surname><given-names>A</given-names></name><name><surname>Van Haute</surname><given-names>LL</given-names></name><name><surname>Vanopdenbosch</surname><given-names>LJ</given-names></name><name><surname>Martin</surname><given-names>J-J</given-names></name><name><surname>Groote</surname><given-names>CC</given-names></name><name><surname>Vandecasteele</surname><given-names>S</given-names></name><name><surname>Boelaert</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Linezolid-induced inhibition of mitochondrial protein synthesis</article-title><source>Clinical Infectious Diseases</source><volume>42</volume><fpage>1111</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1086/501356</pub-id><pub-id pub-id-type="pmid">16575728</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Fusi</surname><given-names>N</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Wilen</surname><given-names>C</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Listgarten</surname><given-names>J</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ealick</surname><given-names>SE</given-names></name><name><surname>Cook</surname><given-names>WJ</given-names></name><name><surname>Vijay-Kumar</surname><given-names>S</given-names></name><name><surname>Carson</surname><given-names>M</given-names></name><name><surname>Nagabhushan</surname><given-names>TL</given-names></name><name><surname>Trotta</surname><given-names>PP</given-names></name><name><surname>Bugg</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Three-dimensional structure of recombinant human interferon-gamma</article-title><source>Science</source><volume>252</volume><fpage>698</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1126/science.1902591</pub-id><pub-id pub-id-type="pmid">1902591</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everts</surname><given-names>B</given-names></name><name><surname>Amiel</surname><given-names>E</given-names></name><name><surname>van der Windt</surname><given-names>GJW</given-names></name><name><surname>Freitas</surname><given-names>TC</given-names></name><name><surname>Chott</surname><given-names>R</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells</article-title><source>Blood</source><volume>120</volume><fpage>1422</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-03-419747</pub-id><pub-id pub-id-type="pmid">22786879</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everts</surname><given-names>B</given-names></name><name><surname>Amiel</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>SC-C</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>C-H</given-names></name><name><surname>Lam</surname><given-names>WY</given-names></name><name><surname>Redmann</surname><given-names>V</given-names></name><name><surname>Freitas</surname><given-names>TC</given-names></name><name><surname>Blagih</surname><given-names>J</given-names></name><name><surname>van der Windt</surname><given-names>GJW</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKɛ supports the anabolic demands of dendritic cell activation</article-title><source>Nature Immunology</source><volume>15</volume><fpage>323</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/ni.2833</pub-id><pub-id pub-id-type="pmid">24562310</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferwerda</surname><given-names>G</given-names></name><name><surname>Girardin</surname><given-names>SE</given-names></name><name><surname>Kullberg</surname><given-names>BJ</given-names></name><name><surname>Le Bourhis</surname><given-names>L</given-names></name><name><surname>de Jong</surname><given-names>DJ</given-names></name><name><surname>Langenberg</surname><given-names>DML</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Adema</surname><given-names>GJ</given-names></name><name><surname>Ottenhoff</surname><given-names>THM</given-names></name><name><surname>Van der Meer</surname><given-names>JWM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis</article-title><source>PLOS Pathogens</source><volume>1</volume><elocation-id>10034</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0010034</pub-id><pub-id pub-id-type="pmid">16322770</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>CS</given-names></name><name><surname>Baixauli</surname><given-names>F</given-names></name><name><surname>Kyle</surname><given-names>RL</given-names></name><name><surname>Puleston</surname><given-names>DJ</given-names></name><name><surname>Cameron</surname><given-names>AM</given-names></name><name><surname>Sanin</surname><given-names>DE</given-names></name><name><surname>Hippen</surname><given-names>KL</given-names></name><name><surname>Loschi</surname><given-names>M</given-names></name><name><surname>Thangavelu</surname><given-names>G</given-names></name><name><surname>Corrado</surname><given-names>M</given-names></name><name><surname>Edwards-Hicks</surname><given-names>J</given-names></name><name><surname>Grzes</surname><given-names>KM</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>422</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.11.021</pub-id><pub-id pub-id-type="pmid">31883840</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipe-Santos</surname><given-names>O</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Chapgier</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>G</given-names></name><name><surname>de Beaucoudrey</surname><given-names>L</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>Fieschi</surname><given-names>C</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features</article-title><source>Seminars in Immunology</source><volume>18</volume><fpage>347</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2006.07.010</pub-id><pub-id pub-id-type="pmid">16997570</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Solache</surname><given-names>A</given-names></name><name><surname>Jaeger</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>PJ</given-names></name><name><surname>Belisle</surname><given-names>JT</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name><name><surname>Rubin</surname><given-names>EJ</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mycobacterium tuberculosis Inhibits Macrophage Responses to IFN-γ through Myeloid Differentiation Factor 88-Dependent and -Independent Mechanisms</article-title><source>The Journal of Immunology</source><volume>172</volume><fpage>6272</fpage><lpage>6280</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.10.6272</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francisco</surname><given-names>LM</given-names></name><name><surname>Sage</surname><given-names>PT</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The PD-1 pathway in tolerance and autoimmunity</article-title><source>Immunological Reviews</source><volume>236</volume><fpage>219</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00923.x</pub-id><pub-id pub-id-type="pmid">20636820</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulco</surname><given-names>CP</given-names></name><name><surname>Munschauer</surname><given-names>M</given-names></name><name><surname>Anyoha</surname><given-names>R</given-names></name><name><surname>Munson</surname><given-names>G</given-names></name><name><surname>Grossman</surname><given-names>SR</given-names></name><name><surname>Perez</surname><given-names>EM</given-names></name><name><surname>Kane</surname><given-names>M</given-names></name><name><surname>Cleary</surname><given-names>B</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Engreitz</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Systematic mapping of functional enhancer-promoter connections with CRISPR interference</article-title><source>Science</source><volume>354</volume><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1126/science.aag2445</pub-id><pub-id pub-id-type="pmid">27708057</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos</surname><given-names>AM</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name><name><surname>Glickman</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection</article-title><source>The Journal of Experimental Medicine</source><volume>205</volume><fpage>2359</fpage><lpage>2368</lpage><pub-id pub-id-type="doi">10.1084/jem.20080353</pub-id><pub-id pub-id-type="pmid">18779346</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Diaz</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><name><surname>Moreno</surname><given-names>BH</given-names></name><name><surname>Saco</surname><given-names>J</given-names></name><name><surname>Escuin-Ordinas</surname><given-names>H</given-names></name><name><surname>Rodriguez</surname><given-names>GA</given-names></name><name><surname>Zaretsky</surname><given-names>JM</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Hugo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Parisi</surname><given-names>G</given-names></name><name><surname>Saus</surname><given-names>CP</given-names></name><name><surname>Torrejon</surname><given-names>DY</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Damoiseaux</surname><given-names>R</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression</article-title><source>Cell Reports</source><volume>19</volume><fpage>1189</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.031</pub-id><pub-id pub-id-type="pmid">28494868</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>F</given-names></name><name><surname>Ruiz-Cabello</surname><given-names>F</given-names></name><name><surname>Cabrera</surname><given-names>T</given-names></name><name><surname>Pérez-Villar</surname><given-names>JJ</given-names></name><name><surname>López-Botet</surname><given-names>M</given-names></name><name><surname>Duggan-Keen</surname><given-names>M</given-names></name><name><surname>Stern</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Implications for immunosurveillance of altered HLA class I phenotypes in human tumours</article-title><source>Immunology Today</source><volume>18</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/s0167-5699(96)10075-x</pub-id><pub-id pub-id-type="pmid">9057360</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>S</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Adeegbe</surname><given-names>D</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Lipschitz</surname><given-names>M</given-names></name><name><surname>Amin-Mansour</surname><given-names>A</given-names></name><name><surname>Raut</surname><given-names>CP</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Hammerman</surname><given-names>P</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Wong</surname><given-names>K-K</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma</article-title><source>Immunity</source><volume>46</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.001</pub-id><pub-id pub-id-type="pmid">28228279</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>B</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Nagano</surname><given-names>S</given-names></name><name><surname>Kumehara</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Besse</surname><given-names>B</given-names></name><name><surname>Yanagitani</surname><given-names>N</given-names></name><name><surname>Friboulet</surname><given-names>L</given-names></name><name><surname>Nishio</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Katayama</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>982</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1084/jem.20180870</pub-id><pub-id pub-id-type="pmid">30872362</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TNF-α promotes IFN-γ-induced CD40 expression and antigen process in Myb-transformed hematological cells</article-title><source>TheScientificWorldJournal</source><volume>2012</volume><elocation-id>621969</elocation-id><pub-id pub-id-type="doi">10.1100/2012/621969</pub-id><pub-id pub-id-type="pmid">22547990</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guak</surname><given-names>H</given-names></name><name><surname>Al Habyan</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>EH</given-names></name><name><surname>Aldossary</surname><given-names>H</given-names></name><name><surname>Al-Masri</surname><given-names>M</given-names></name><name><surname>Won</surname><given-names>SY</given-names></name><name><surname>Ying</surname><given-names>T</given-names></name><name><surname>Fixman</surname><given-names>ED</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>McCaffrey</surname><given-names>LM</given-names></name><name><surname>Krawczyk</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Glycolytic metabolism is essential for CCR7 oligomerization and dendritic cell migration</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2463</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04804-6</pub-id><pub-id pub-id-type="pmid">29941886</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassounah</surname><given-names>NB</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Freeman</surname><given-names>SS</given-names></name><name><surname>Beauchamp</surname><given-names>EM</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Souders</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>Akbay</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification and characterization of an alternative cancer-derived PD-L1 splice variant</article-title><source>Cancer Immunology, Immunotherapy</source><volume>68</volume><fpage>407</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-2284-z</pub-id><pub-id pub-id-type="pmid">30564890</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>TSP</given-names></name><name><surname>Painter</surname><given-names>MW</given-names></name><collab>Immunological Genome Project Consortium</collab></person-group><year iso-8601-date="2008">2008</year><article-title>The Immunological Genome Project: networks of gene expression in immune cells</article-title><source>Nature Immunology</source><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/ni1008-1091</pub-id><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname><given-names>C</given-names></name><name><surname>Marqués</surname><given-names>L</given-names></name><name><surname>Lloberas</surname><given-names>J</given-names></name><name><surname>Celada</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice</article-title><source>The Journal of Clinical Investigation</source><volume>107</volume><fpage>485</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1172/JCI11696</pub-id><pub-id pub-id-type="pmid">11181648</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horlbeck</surname><given-names>MA</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>NK</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Bogdanoff</surname><given-names>D</given-names></name><name><surname>Adamson</surname><given-names>B</given-names></name><name><surname>Chow</surname><given-names>ED</given-names></name><name><surname>Kampmann</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>TR</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Fischbach</surname><given-names>MA</given-names></name><name><surname>Weissman</surname><given-names>JS</given-names></name><name><surname>Gilbert</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping the Genetic Landscape of Human Cells</article-title><source>Cell</source><volume>174</volume><fpage>953</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.010</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases</article-title><source>Immunity</source><volume>31</volume><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2009.09.002</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>IFNγ: signalling, Epigenetics and Roles in Immunity, Metabolism, Disease and Cancer Immunotherapy</article-title><source>Nature Reviews Immunology</source><volume>18</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0029-z</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Javadov</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>OPA1 regulates respiratory supercomplexes assembly: The role of mitochondrial swelling</article-title><source>Mitochondrion</source><volume>51</volume><fpage>30</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2019.11.006</pub-id><pub-id pub-id-type="pmid">31870826</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jha</surname><given-names>AK</given-names></name><name><surname>Huang</surname><given-names>SC-C</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name><name><surname>Lampropoulou</surname><given-names>V</given-names></name><name><surname>Ivanova</surname><given-names>Y</given-names></name><name><surname>Loginicheva</surname><given-names>E</given-names></name><name><surname>Chmielewski</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>KM</given-names></name><name><surname>Ashall</surname><given-names>J</given-names></name><name><surname>Everts</surname><given-names>B</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Driggers</surname><given-names>EM</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization</article-title><source>Immunity</source><volume>42</volume><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.005</pub-id><pub-id pub-id-type="pmid">25786174</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A permutation-based non-parametric analysis of CRISPR screen data</article-title><source>BMC Genomics</source><volume>18</volume><elocation-id>545</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-017-3938-5</pub-id><pub-id pub-id-type="pmid">28724352</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Léger</surname><given-names>C</given-names></name><name><surname>Hasbold</surname><given-names>J</given-names></name><name><surname>Holman</surname><given-names>M</given-names></name><name><surname>Klaus</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The effects of IFN-gamma on CD40-mediated activation of B cells from X-linked immunodeficient or normal mice</article-title><source>Journal of Immunology</source><volume>159</volume><fpage>1150</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">9233608</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Altare</surname><given-names>F</given-names></name><name><surname>Lamhamedi</surname><given-names>S</given-names></name><name><surname>Revy</surname><given-names>P</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Newport</surname><given-names>M</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Seboun</surname><given-names>E</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection</article-title><source>The New England Journal of Medicine</source><volume>335</volume><fpage>1956</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1056/NEJM199612263352604</pub-id><pub-id pub-id-type="pmid">8960475</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Brigham</surname><given-names>MD</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</article-title><source>Nature Protocols</source><volume>12</volume><fpage>828</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id><pub-id pub-id-type="pmid">28333914</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>S-B</given-names></name><name><surname>Choi</surname><given-names>MJ</given-names></name><name><surname>Ryu</surname><given-names>D</given-names></name><name><surname>Yi</surname><given-names>H-S</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Chung</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Kang</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>C-S</given-names></name><name><surname>Lee</surname><given-names>C-H</given-names></name><name><surname>Williams</surname><given-names>RW</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Shong</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reduced oxidative capacity in macrophages results in systemic insulin resistance</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1551</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-03998-z</pub-id><pub-id pub-id-type="pmid">29674655</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Nagano</surname><given-names>S</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Kitanaka</surname><given-names>A</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Watatani</surname><given-names>Y</given-names></name><name><surname>Kakiuchi</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Yoshizato</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Itonaga</surname><given-names>H</given-names></name><name><surname>Imaizumi</surname><given-names>Y</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Munakata</surname><given-names>W</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Hama</surname><given-names>N</given-names></name><name><surname>Shide</surname><given-names>K</given-names></name><name><surname>Kubuki</surname><given-names>Y</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Kameda</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Minato</surname><given-names>N</given-names></name><name><surname>Kashiwase</surname><given-names>K</given-names></name><name><surname>Izutsu</surname><given-names>K</given-names></name><name><surname>Takaori-Kondo</surname><given-names>A</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Kawamoto</surname><given-names>H</given-names></name><name><surname>Akatsuka</surname><given-names>Y</given-names></name><name><surname>Shimoda</surname><given-names>K</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Seya</surname><given-names>T</given-names></name><name><surname>Miyano</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers</article-title><source>Nature</source><volume>534</volume><fpage>402</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1038/nature18294</pub-id><pub-id pub-id-type="pmid">27281199</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kincaid</surname><given-names>EZ</given-names></name><name><surname>Wolf</surname><given-names>AJ</given-names></name><name><surname>Desvignes</surname><given-names>L</given-names></name><name><surname>Mahapatra</surname><given-names>S</given-names></name><name><surname>Crick</surname><given-names>DC</given-names></name><name><surname>Brennan</surname><given-names>PJ</given-names></name><name><surname>Pavelka</surname><given-names>MS</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Codominance of TLR2-dependent and TLR2-independent modulation of MHC class II in Mycobacterium tuberculosis infection in vivo</article-title><source>Journal of Immunology</source><volume>179</volume><fpage>3187</fpage><lpage>3195</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.5.3187</pub-id><pub-id pub-id-type="pmid">17709534</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiritsy</surname><given-names>MC</given-names></name><name><surname>Ankley</surname><given-names>LM</given-names></name><name><surname>Trombley</surname><given-names>J</given-names></name><name><surname>Huizinga</surname><given-names>GP</given-names></name><name><surname>Lord</surname><given-names>AE</given-names></name><name><surname>Orning</surname><given-names>P</given-names></name><name><surname>Elling</surname><given-names>R</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Olive</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A genetic screen in macrophages identifies new regulators of IFNγ-inducible MHCII that contribute to T cell activation</article-title><source>eLife</source><volume>10</volume><elocation-id>e65102</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.65110</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>XF</given-names></name><name><surname>Vogt</surname><given-names>G</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Macura-Biegun</surname><given-names>A</given-names></name><name><surname>Szaflarska</surname><given-names>A</given-names></name><name><surname>Kowalczyk</surname><given-names>D</given-names></name><name><surname>Chapgier</surname><given-names>A</given-names></name><name><surname>Abhyankar</surname><given-names>A</given-names></name><name><surname>Furthner</surname><given-names>D</given-names></name><name><surname>Djambas Khayat</surname><given-names>C</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Bryant</surname><given-names>VL</given-names></name><name><surname>Bogunovic</surname><given-names>D</given-names></name><name><surname>Kreins</surname><given-names>A</given-names></name><name><surname>Moncada-Vélez</surname><given-names>M</given-names></name><name><surname>Migaud</surname><given-names>M</given-names></name><name><surname>Al-Ajaji</surname><given-names>S</given-names></name><name><surname>Al-Muhsen</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Chaussabel</surname><given-names>D</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease</article-title><source>Human Molecular Genetics</source><volume>22</volume><fpage>769</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds484</pub-id><pub-id pub-id-type="pmid">23161749</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krawczyk</surname><given-names>CM</given-names></name><name><surname>Holowka</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Blagih</surname><given-names>J</given-names></name><name><surname>Amiel</surname><given-names>E</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Jung</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation</article-title><source>Blood</source><volume>115</volume><fpage>4742</fpage><lpage>4749</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-249540</pub-id><pub-id pub-id-type="pmid">20351312</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriegsman</surname><given-names>BA</given-names></name><name><surname>Vangala</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>BJ</given-names></name><name><surname>Meraner</surname><given-names>P</given-names></name><name><surname>Brass</surname><given-names>AL</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression</article-title><source>Journal of Immunology</source><volume>203</volume><fpage>1999</fpage><lpage>2010</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1900475</pub-id><pub-id pub-id-type="pmid">31471524</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasfar</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Cohen Solal</surname><given-names>KA</given-names></name><name><surname>Reuhl</surname><given-names>K</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><name><surname>Langer</surname><given-names>JA</given-names></name><name><surname>Laskin</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response</article-title><source>Immunology</source><volume>142</volume><fpage>442</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1111/imm.12273</pub-id><pub-id pub-id-type="pmid">24597649</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarou</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>M</given-names></name><name><surname>Ohtake</surname><given-names>A</given-names></name><name><surname>Thorburn</surname><given-names>DR</given-names></name><name><surname>Ryan</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Analysis of the Assembly Profiles for Mitochondrial- and Nuclear-DNA-Encoded Subunits into Complex I</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>4228</fpage><lpage>4237</lpage><pub-id pub-id-type="doi">10.1128/MCB.00074-07</pub-id><pub-id pub-id-type="pmid">17438127</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lees</surname><given-names>JR</given-names></name><name><surname>Cross</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A little stress is good: IFN-gamma, demyelination, and multiple sclerosis</article-title><source>The Journal of Clinical Investigation</source><volume>117</volume><fpage>297</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1172/JCI31254</pub-id><pub-id pub-id-type="pmid">17273549</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtonen</surname><given-names>A</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name><name><surname>Julkunen</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages</article-title><source>Journal of Immunology</source><volume>159</volume><fpage>794</fpage><lpage>803</lpage></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Köster</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C-H</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR</article-title><source>Genome Biology</source><volume>16</volume><elocation-id>281</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0843-6</pub-id><pub-id pub-id-type="pmid">26673418</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>X</given-names></name><name><surname>Kushner</surname><given-names>SA</given-names></name><name><surname>Chung</surname><given-names>CD</given-names></name><name><surname>Chang</surname><given-names>DD</given-names></name><name><surname>Shuai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Inhibition of Stat1-mediated gene activation by PIAS1</article-title><source>PNAS</source><volume>95</volume><fpage>10626</fpage><lpage>10631</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.18.10626</pub-id><pub-id pub-id-type="pmid">9724754</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PS</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chao</surname><given-names>T</given-names></name><name><surname>Teav</surname><given-names>T</given-names></name><name><surname>Christen</surname><given-names>S</given-names></name><name><surname>Di Conza</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>WC</given-names></name><name><surname>Chou</surname><given-names>CH</given-names></name><name><surname>Vavakova</surname><given-names>M</given-names></name><name><surname>Muret</surname><given-names>C</given-names></name><name><surname>Debackere</surname><given-names>K</given-names></name><name><surname>Mazzone</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>HD</given-names></name><name><surname>Fendt</surname><given-names>SM</given-names></name><name><surname>Ivanisevic</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming</article-title><source>Nature Immunology</source><volume>18</volume><fpage>985</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/ni.3796</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Lv</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zong</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>110</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.10.021</pub-id><pub-id pub-id-type="pmid">33171124</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyford-Pike</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>GD</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Akpeng</surname><given-names>B</given-names></name><name><surname>Bruno</surname><given-names>TC</given-names></name><name><surname>Richmon</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bishop</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Pai</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma</article-title><source>Cancer Research</source><volume>73</volume><fpage>1733</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2384</pub-id><pub-id pub-id-type="pmid">23288508</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>KM</given-names></name><name><surname>Shukla</surname><given-names>SA</given-names></name><name><surname>Patsoukis</surname><given-names>N</given-names></name><name><surname>Chaudhri</surname><given-names>A</given-names></name><name><surname>Browne</surname><given-names>EP</given-names></name><name><surname>Arazi</surname><given-names>A</given-names></name><name><surname>Eisenhaure</surname><given-names>TM</given-names></name><name><surname>Hua</surname><given-names>P</given-names></name><name><surname>Pham</surname><given-names>HC</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Fritsch</surname><given-names>EF</given-names></name><name><surname>Boussiotis</surname><given-names>VA</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression</article-title><source>Cancer Immunology, Immunotherapy</source><volume>68</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/s00262-018-2282-1</pub-id><pub-id pub-id-type="pmid">30564891</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manguso</surname><given-names>RT</given-names></name><name><surname>Pope</surname><given-names>HW</given-names></name><name><surname>Zimmer</surname><given-names>MD</given-names></name><name><surname>Brown</surname><given-names>FD</given-names></name><name><surname>Yates</surname><given-names>KB</given-names></name><name><surname>Miller</surname><given-names>BC</given-names></name><name><surname>Collins</surname><given-names>NB</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>LaFleur</surname><given-names>MW</given-names></name><name><surname>Juneja</surname><given-names>VR</given-names></name><name><surname>Weiss</surname><given-names>SA</given-names></name><name><surname>Lo</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>E</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target</article-title><source>Nature</source><volume>547</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1038/nature23270</pub-id><pub-id pub-id-type="pmid">28723893</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAdam</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells</article-title><source>Immunological Reviews</source><volume>165</volume><fpage>231</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065x.1998.tb01242.x</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meraz</surname><given-names>MA</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Sheehan</surname><given-names>KC</given-names></name><name><surname>Bach</surname><given-names>EA</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Dighe</surname><given-names>AS</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name><name><surname>Riley</surname><given-names>JK</given-names></name><name><surname>Greenlund</surname><given-names>AC</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Carver-Moore</surname><given-names>K</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway</article-title><source>Cell</source><volume>84</volume><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81288-x</pub-id><pub-id pub-id-type="pmid">8608597</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Isserlin</surname><given-names>R</given-names></name><name><surname>Stueker</surname><given-names>O</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Enrichment map: A network-based method for gene-set enrichment visualization and interpretation</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13984</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013984</pub-id><pub-id pub-id-type="pmid">21085593</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mezzadra</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Jae</surname><given-names>LT</given-names></name><name><surname>Gomez-Eerland</surname><given-names>R</given-names></name><name><surname>de Vries</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Logtenberg</surname><given-names>MEW</given-names></name><name><surname>Slagter</surname><given-names>M</given-names></name><name><surname>Rozeman</surname><given-names>EA</given-names></name><name><surname>Hofland</surname><given-names>I</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Wessels</surname><given-names>LFA</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Brummelkamp</surname><given-names>TR</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of CMTM6 and CMTM4 as PD-L1 protein regulators</article-title><source>Nature</source><volume>549</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature23669</pub-id><pub-id pub-id-type="pmid">28813410</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Logan</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>ASH</given-names></name><name><surname>Varma</surname><given-names>M</given-names></name><name><surname>Bryant</surname><given-names>CE</given-names></name><name><surname>Tourlomousis</surname><given-names>P</given-names></name><name><surname>Däbritz</surname><given-names>JHM</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Latorre</surname><given-names>I</given-names></name><name><surname>Corr</surname><given-names>SC</given-names></name><name><surname>McManus</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>D</given-names></name><name><surname>Jacobs</surname><given-names>HT</given-names></name><name><surname>Szibor</surname><given-names>M</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages</article-title><source>Cell</source><volume>167</volume><fpage>457</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.064</pub-id><pub-id pub-id-type="pmid">27667687</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EL</given-names></name><name><surname>Ryan</surname><given-names>DG</given-names></name><name><surname>Prag</surname><given-names>HA</given-names></name><name><surname>Dikovskaya</surname><given-names>D</given-names></name><name><surname>Menon</surname><given-names>D</given-names></name><name><surname>Zaslona</surname><given-names>Z</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Costa</surname><given-names>ASH</given-names></name><name><surname>Higgins</surname><given-names>M</given-names></name><name><surname>Hams</surname><given-names>E</given-names></name><name><surname>Szpyt</surname><given-names>J</given-names></name><name><surname>Runtsch</surname><given-names>MC</given-names></name><name><surname>King</surname><given-names>MS</given-names></name><name><surname>McGouran</surname><given-names>JF</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Hughes</surname><given-names>MM</given-names></name><name><surname>Carroll</surname><given-names>RG</given-names></name><name><surname>Booty</surname><given-names>LM</given-names></name><name><surname>Knatko</surname><given-names>EV</given-names></name><name><surname>Meakin</surname><given-names>PJ</given-names></name><name><surname>Ashford</surname><given-names>MLJ</given-names></name><name><surname>Modis</surname><given-names>LK</given-names></name><name><surname>Brunori</surname><given-names>G</given-names></name><name><surname>Sévin</surname><given-names>DC</given-names></name><name><surname>Fallon</surname><given-names>PG</given-names></name><name><surname>Caldwell</surname><given-names>ST</given-names></name><name><surname>Kunji</surname><given-names>ERS</given-names></name><name><surname>Chouchani</surname><given-names>ET</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><name><surname>Hartley</surname><given-names>RC</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>O’Neill</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1</article-title><source>Nature</source><volume>556</volume><fpage>113</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature25986</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>PS</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Moon</surname><given-names>PK</given-names></name><name><surname>Joshi</surname><given-names>AU</given-names></name><name><surname>Dove</surname><given-names>C</given-names></name><name><surname>Mhatre</surname><given-names>S</given-names></name><name><surname>Contrepois</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>BA</given-names></name><name><surname>Coronado</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Migaud</surname><given-names>M</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Andreasson</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation</article-title><source>Nature Immunology</source><volume>20</volume><fpage>50</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0255-3</pub-id><pub-id pub-id-type="pmid">30478397</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>BB</given-names></name><name><surname>Rathinam</surname><given-names>VAK</given-names></name><name><surname>Martens</surname><given-names>GW</given-names></name><name><surname>Martinot</surname><given-names>AJ</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Sassetti</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β</article-title><source>Nature Immunology</source><volume>14</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/ni.2474</pub-id><pub-id pub-id-type="pmid">23160153</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>GJ</given-names></name><name><surname>Richmond</surname><given-names>JFL</given-names></name><name><surname>Schlesinger</surname><given-names>A</given-names></name><name><surname>Jennings</surname><given-names>EG</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human macrophage activation programs induced by bacterial pathogens</article-title><source>PNAS</source><volume>99</volume><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1073/pnas.022649799</pub-id><pub-id pub-id-type="pmid">11805289</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newport</surname><given-names>MJ</given-names></name><name><surname>Huxley</surname><given-names>CM</given-names></name><name><surname>Huston</surname><given-names>S</given-names></name><name><surname>Hawrylowicz</surname><given-names>CM</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Williamson</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection</article-title><source>The New England Journal of Medicine</source><volume>335</volume><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1056/NEJM199612263352602</pub-id><pub-id pub-id-type="pmid">8960473</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Shea</surname><given-names>JJ</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of T(H)1 differentiation--controlling the controllers</article-title><source>Nature Immunology</source><volume>3</volume><fpage>506</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/ni0602-506</pub-id><pub-id pub-id-type="pmid">12032561</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliarini</surname><given-names>DJ</given-names></name><name><surname>Calvo</surname><given-names>SE</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Sheth</surname><given-names>SA</given-names></name><name><surname>Vafai</surname><given-names>SB</given-names></name><name><surname>Ong</surname><given-names>SE</given-names></name><name><surname>Walford</surname><given-names>GA</given-names></name><name><surname>Sugiana</surname><given-names>C</given-names></name><name><surname>Boneh</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>WK</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>JG</given-names></name><name><surname>Thorburn</surname><given-names>DR</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A mitochondrial protein compendium elucidates complex I disease biology</article-title><source>Cell</source><volume>134</volume><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.06.016</pub-id><pub-id pub-id-type="pmid">18614015</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>EM</given-names></name><name><surname>Gonzalez-Cotto</surname><given-names>M</given-names></name><name><surname>Baseler</surname><given-names>WA</given-names></name><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Ghesquière</surname><given-names>B</given-names></name><name><surname>Maio</surname><given-names>N</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Rouault</surname><given-names>TA</given-names></name><name><surname>Cassel</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>RM</given-names></name><name><surname>Lane</surname><given-names>AN</given-names></name><name><surname>Fan</surname><given-names>TW-M</given-names></name><name><surname>Wink</surname><given-names>DA</given-names></name><name><surname>McVicar</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>698</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14433-7</pub-id><pub-id pub-id-type="pmid">32019928</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>E</given-names></name><name><surname>Butler</surname><given-names>AW</given-names></name><name><surname>Foster</surname><given-names>S</given-names></name><name><surname>Bracken</surname><given-names>B</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name><name><surname>Wessels</surname><given-names>HH</given-names></name><name><surname>Yeung</surname><given-names>BZ</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterizing the Molecular Regulation of Inhibitory Immune Checkpoints with Multi-Modal Single-Cell Screens</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.06.28.175596</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestka</surname><given-names>S</given-names></name><name><surname>Krause</surname><given-names>CD</given-names></name><name><surname>Walter</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Interferons, interferon-like cytokines, and their receptors</article-title><source>Immunological Reviews</source><volume>202</volume><fpage>8</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00204.x</pub-id><pub-id pub-id-type="pmid">15546383</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollard</surname><given-names>KM</given-names></name><name><surname>Cauvi</surname><given-names>DM</given-names></name><name><surname>Toomey</surname><given-names>CB</given-names></name><name><surname>Morris</surname><given-names>KV</given-names></name><name><surname>Kono</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Interferon-γ and systemic autoimmunity</article-title><source>Discovery Medicine</source><volume>16</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">23998448</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redecke</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Chaturvedi</surname><given-names>V</given-names></name><name><surname>High</surname><given-names>AA</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hematopoietic progenitor cell lines with myeloid and lymphoid potential</article-title><source>Nature Methods</source><volume>10</volume><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2510</pub-id><pub-id pub-id-type="pmid">23749299</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimand</surname><given-names>J</given-names></name><name><surname>Isserlin</surname><given-names>R</given-names></name><name><surname>Voisin</surname><given-names>V</given-names></name><name><surname>Kucera</surname><given-names>M</given-names></name><name><surname>Tannus-Lopes</surname><given-names>C</given-names></name><name><surname>Rostamianfar</surname><given-names>A</given-names></name><name><surname>Wadi</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Merico</surname><given-names>D</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap</article-title><source>Nature Protocols</source><volume>14</volume><fpage>482</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0103-9</pub-id><pub-id pub-id-type="pmid">30664679</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name><name><surname>Waldburger</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of MHC class II gene expression by the class II transactivator</article-title><source>Nature Reviews. Immunology</source><volume>5</volume><fpage>793</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1038/nri1708</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>KL</given-names></name><name><surname>Reits</surname><given-names>E</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Present Yourself! By MHC Class I and MHC Class II Molecules</article-title><source>Trends in Immunology</source><volume>37</volume><fpage>724</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.it.2016.08.010</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schildberg</surname><given-names>FA</given-names></name><name><surname>Klein</surname><given-names>SR</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family</article-title><source>Immunity</source><volume>44</volume><fpage>955</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.002</pub-id><pub-id pub-id-type="pmid">27192563</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnare</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>GM</given-names></name><name><surname>Holt</surname><given-names>AC</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Toll-like receptors control activation of adaptive immune responses</article-title><source>Nature Immunology</source><volume>2</volume><fpage>947</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1038/ni712</pub-id><pub-id pub-id-type="pmid">11547333</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>BE</given-names></name><name><surname>Korbel</surname><given-names>D</given-names></name><name><surname>Hagens</surname><given-names>K</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Raupach</surname><given-names>B</given-names></name><name><surname>Enders</surname><given-names>J</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Mittrücker</surname><given-names>HW</given-names></name><name><surname>Schaible</surname><given-names>UE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A role for IL-18 in protective immunity against Mycobacterium tuberculosis</article-title><source>European Journal of Immunology</source><volume>40</volume><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/eji.200939583</pub-id><pub-id pub-id-type="pmid">19950174</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>K</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><name><surname>Ravasi</surname><given-names>T</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Interferon-gamma: an overview of signals, mechanisms and functions</article-title><source>Journal of Leukocyte Biology</source><volume>75</volume><fpage>163</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1189/jlb.0603252</pub-id><pub-id pub-id-type="pmid">14525967</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia-inducible factors in physiology and medicine</article-title><source>Cell</source><volume>148</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.021</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mechanisms of costimulation</article-title><source>Immunological Reviews</source><volume>229</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00784.x</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Introduction to checkpoint inhibitors and cancer immunotherapy</article-title><source>Immunological Reviews</source><volume>276</volume><fpage>5</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/imr.12531</pub-id><pub-id pub-id-type="pmid">28258698</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>A</given-names></name><name><surname>Miró</surname><given-names>O</given-names></name><name><surname>Mensa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mitochondrial Toxicity Associated with Linezolid</article-title><source>The New England Journal of Medicine</source><volume>353</volume><fpage>2305</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1056/NEJM200511243532123</pub-id><pub-id pub-id-type="pmid">16306535</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Mottet</surname><given-names>A</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA</article-title><source>Science</source><volume>265</volume><fpage>106</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1126/science.8016643</pub-id><pub-id pub-id-type="pmid">8016643</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Durand</surname><given-names>B</given-names></name><name><surname>Barras</surname><given-names>E</given-names></name><name><surname>Zufferey</surname><given-names>M</given-names></name><name><surname>Hadam</surname><given-names>MR</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)</article-title><source>Genes &amp; Development</source><volume>9</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1101/gad.9.9.1021</pub-id><pub-id pub-id-type="pmid">7744245</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroud</surname><given-names>DA</given-names></name><name><surname>Surgenor</surname><given-names>EE</given-names></name><name><surname>Formosa</surname><given-names>LE</given-names></name><name><surname>Reljic</surname><given-names>B</given-names></name><name><surname>Frazier</surname><given-names>AE</given-names></name><name><surname>Dibley</surname><given-names>MG</given-names></name><name><surname>Osellame</surname><given-names>LD</given-names></name><name><surname>Stait</surname><given-names>T</given-names></name><name><surname>Beilharz</surname><given-names>TH</given-names></name><name><surname>Thorburn</surname><given-names>DR</given-names></name><name><surname>Salim</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Accessory subunits are integral for assembly and function of human mitochondrial complex I</article-title><source>Nature</source><volume>538</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nature19754</pub-id><pub-id pub-id-type="pmid">27626371</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Giannopoulou</surname><given-names>EG</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Rätsch</surname><given-names>G</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Ivashkiv</surname><given-names>LB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation</article-title><source>Nature Immunology</source><volume>16</volume><fpage>838</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1038/ni.3205</pub-id><pub-id pub-id-type="pmid">26147685</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Miettinen</surname><given-names>TP</given-names></name><name><surname>Mu</surname><given-names>L</given-names></name><name><surname>Mirek</surname><given-names>E</given-names></name><name><surname>Manalis</surname><given-names>SR</given-names></name><name><surname>Anthony</surname><given-names>TG</given-names></name><name><surname>Sesaki</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Disassembly of ETC Complexes Drives Macrophage Inflammatory Responses by Reprogramming Cellular Metabolism and Translation</article-title><source>SSRN Electronic Journal</source><volume>2020</volume><elocation-id>3611881</elocation-id><pub-id pub-id-type="doi">10.2139/ssrn.3611881</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannahill</surname><given-names>GM</given-names></name><name><surname>Curtis</surname><given-names>AM</given-names></name><name><surname>Adamik</surname><given-names>J</given-names></name><name><surname>Palsson-McDermott</surname><given-names>EM</given-names></name><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Goel</surname><given-names>G</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>NJ</given-names></name><name><surname>Kelly</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>NH</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Gardet</surname><given-names>A</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Jany</surname><given-names>SS</given-names></name><name><surname>Corr</surname><given-names>SC</given-names></name><name><surname>Haneklaus</surname><given-names>M</given-names></name><name><surname>Caffrey</surname><given-names>BE</given-names></name><name><surname>Pierce</surname><given-names>K</given-names></name><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Beasley</surname><given-names>FC</given-names></name><name><surname>Cummins</surname><given-names>E</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name><name><surname>Whyte</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Kelly</surname><given-names>VP</given-names></name><name><surname>Clish</surname><given-names>C</given-names></name><name><surname>Auron</surname><given-names>PE</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Succinate is an inflammatory signal that induces IL-1β through HIF-1α</article-title><source>Nature</source><volume>496</volume><fpage>238</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nature11986</pub-id><pub-id pub-id-type="pmid">23535595</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>J</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Genetic Control of MHC Class II Expression</article-title><source>Cell</source><volume>109</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00696-7</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name><name><surname>Torigoe</surname><given-names>K</given-names></name><name><surname>Kurimoto</surname><given-names>M</given-names></name><name><surname>Matsui</surname><given-names>K</given-names></name><name><surname>Hada</surname><given-names>T</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells</article-title><source>Ternational Immunology</source><volume>12</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1093/intimm/12.2.151</pub-id><pub-id pub-id-type="pmid">10653850</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Interleukin-12 and the regulation of innate resistance and adaptive immunity</article-title><source>Nature Reviews. Immunology</source><volume>3</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nri1001</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Rhijn</surname><given-names>I</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Moody</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lipid and small-molecule display by CD1 and MR1</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>643</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/nri3889</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhoen</surname><given-names>M</given-names></name><name><surname>Blankenhaus</surname><given-names>B</given-names></name><name><surname>Konjar</surname><given-names>Š</given-names></name><name><surname>Ferreira</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic wiring of murine T cell and intraepithelial lymphocyte maintenance and activation</article-title><source>European Journal of Immunology</source><volume>48</volume><fpage>1430</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1002/eji.201646745</pub-id><pub-id pub-id-type="pmid">30043974</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venter</surname><given-names>G</given-names></name><name><surname>Oerlemans</surname><given-names>FTJJ</given-names></name><name><surname>Willemse</surname><given-names>M</given-names></name><name><surname>Wijers</surname><given-names>M</given-names></name><name><surname>Fransen</surname><given-names>JAM</given-names></name><name><surname>Wieringa</surname><given-names>B</given-names></name><name><surname>Dzeja</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NAMPT-Mediated Salvage Synthesis of NAD+ Controls Morphofunctional Changes of Macrophages</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e97378</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0097378</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walser</surname><given-names>TC</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Kundu</surname><given-names>N</given-names></name><name><surname>Dorsey</surname><given-names>R</given-names></name><name><surname>Goloubeva</surname><given-names>O</given-names></name><name><surname>Fulton</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model</article-title><source>Journal of Immunotherapy</source><volume>30</volume><fpage>490</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e318031b551</pub-id><pub-id pub-id-type="pmid">17589289</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Calvo</surname><given-names>KR</given-names></name><name><surname>Pasillas</surname><given-names>MP</given-names></name><name><surname>Sykes</surname><given-names>DB</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name><name><surname>Kamps</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8</article-title><source>Nature Methods</source><volume>3</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nmeth865</pub-id><pub-id pub-id-type="pmid">16554834</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>R</given-names></name><name><surname>Vuckovic</surname><given-names>I</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Folmes</surname><given-names>CD</given-names></name><name><surname>Dzeja</surname><given-names>PD</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity</article-title><source>EBioMedicine</source><volume>30</volume><fpage>303</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.02.009</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Linghu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J-S</given-names></name><name><surname>You</surname><given-names>H</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>755</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08680-6</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheelock</surname><given-names>EF</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin</article-title><source>Science</source><volume>149</volume><fpage>310</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1126/science.149.3681.310</pub-id><pub-id pub-id-type="pmid">17838106</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijdeven</surname><given-names>RH</given-names></name><name><surname>van Luijn</surname><given-names>MM</given-names></name><name><surname>Wierenga-Wolf</surname><given-names>AF</given-names></name><name><surname>Akkermans</surname><given-names>JJ</given-names></name><name><surname>van den Elsen</surname><given-names>PJ</given-names></name><name><surname>Hintzen</surname><given-names>RQ</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Chemical and genetic control of IFNγ-induced MHCII expression</article-title><source>EMBO Reports</source><volume>19</volume><elocation-id>e45553</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201745553</pub-id><pub-id pub-id-type="pmid">30021835</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>DN</given-names></name><name><surname>Schluenzen</surname><given-names>F</given-names></name><name><surname>Harms</surname><given-names>JM</given-names></name><name><surname>Starosta</surname><given-names>AL</given-names></name><name><surname>Connell</surname><given-names>SR</given-names></name><name><surname>Fucini</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning</article-title><source>PNAS</source><volume>105</volume><fpage>13339</fpage><lpage>13344</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804276105</pub-id><pub-id pub-id-type="pmid">18757750</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>T</given-names></name><name><surname>Akiba</surname><given-names>H</given-names></name><name><surname>Iwai</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Tanno</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Expression of programmed death 1 ligands by murine T cells and APC</article-title><source>Journal of Immunology</source><volume>169</volume><fpage>5538</fpage><lpage>5545</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.10.5538</pub-id><pub-id pub-id-type="pmid">12421930</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Vinothkumar</surname><given-names>KR</given-names></name><name><surname>Hirst</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure of mammalian respiratory complex I</article-title><source>Nature</source><volume>536</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/nature19095</pub-id><pub-id pub-id-type="pmid">27509854</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zickermann</surname><given-names>V</given-names></name><name><surname>Wirth</surname><given-names>C</given-names></name><name><surname>Nasiri</surname><given-names>H</given-names></name><name><surname>Siegmund</surname><given-names>K</given-names></name><name><surname>Schwalbe</surname><given-names>H</given-names></name><name><surname>Hunte</surname><given-names>C</given-names></name><name><surname>Brandt</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural biology. Mechanistic insight from the crystal structure of mitochondrial complex I</article-title><source>Science</source><volume>347</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1126/science.1259859</pub-id><pub-id pub-id-type="pmid">25554780</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65109.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group></front-stub><body><p>In this article, Olive and colleagues used a genetic screen to identify complex I (CI) of the electron transport chain (ETC) as a regulator of IFNγ-mediated gene expression in macrophages. They attribute this role of CI to effects on the activity of the JAK-STAT pathway downstream of the IFNγ receptor. That CI (or perhaps ETC) activity can acutely regulate JAK-STAT signaling has interesting implications for the metabolic regulation of signal transduction, and the underpinning basis would be important to elucidate in future studies.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65109.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Horng</surname><given-names>Tiffany</given-names></name><role>Reviewing Editor</role><aff><institution>Shanghai Tech University</institution><country>China</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zanoni</surname><given-names>Ivan</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Mitochondrial respiration contributes to the interferon γ response in antigen presenting cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Wendy Garrett as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Ivan Zanoni (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at eLife&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>In this manuscript, Olive and colleagues used a genetic screen to identify Complex I (CI) of the electron transport chain (ETC) as a regulator of IFNγ-mediated gene expression in macrophages. They attribute this role of CI to effects on the activity of the JAK-STAT pathway downstream of the IFNγ receptor.</p><p>While a potential link between CI activity and the activity of the JAK-STAT pathway would be interesting, the reviewers think that additional analyses are needed to substantiate this claim and rule out alternative interpretations.</p><p>Essential revisions:</p><p>1. Lines 204-205: The authors find that sgRNAs targeting other complexes of the ETC, including CIII and CIV, had no effect on the ability of IFNγ to stimulate expression of cell surface markers. How do the authors interpret these findings, since CI does not work in isolation in the ETC and is rather dependent on CIII and CIV activity?</p><p>2. How does IFNγ stimulation affect oxidative metabolism as assessed by Seahorse? In order to corroborate the authors' conclusions regarding activity of individual ETC complexes (point 1 above), Seahorse analysis of individual complexes is also advised.</p><p>3. The authors do some limited analyses in human MDMs to suggest that their findings in the mouse macrophage cell line can be generalized to other macrophage populations. It would be great if the analyses in the human MDMs could be extended to further strengthen the generality of their central findings.</p><p>4. Figure 6D: Not clear whether similar exposures were used in different panels. Would be better to load samples in the same gel so that the same exposure can be used and a direct comparison between conditions can be made.</p><p>5. Figure 6D: Does acute treatment with rotenone (but not inhibitors of other ETC complexes) have similar effects in reducing JAK-STAT signaling as knockdown of CI subunits? If not, then stable, long-term knockdown of CI subunits may have some effect independent of respiration in influencing JAK-STAT signaling (for example, on expression of some component of the JAK-STAT pathway). This interpretation could also explain why knockdown of other components of the ETC do not have similar effects to CI. Rotenone treatment could be tried (and compared with inhibitors of other ETC complexes), and if the data are different from knockdown of CI subunits, then related data in the study could be re-interpreted and conclusions modified.</p><p>6. In Figure 3H a key control is missing. What about survival of the cells when the import of the only energy substrate is blocked?</p><p>7. The authors could consider placing their findings in the context of the broader literature. (As just one example, Ivashkiv Nat Imm 2015 described a role for mTORC1 and metabolism in IFNγ-mediated transcriptional and translational regulation in macrophages.) This would increase the impact of their findings.</p><p><italic>Reviewer #1:</italic></p><p>In this manuscript, Olive and colleagues used a genetic screen to identify mitochondrial Complex I as a regulator of IFNγ-mediated gene expression in macrophages. They attribute this role of CI to effects on the activity of the JAK-STAT pathway downstream of the IFNγ receptor. They show that T cell stimulatory activity is a consequence of CI activity.</p><p>There are some questions regarding the authors' proposed mechanism for how CI activity influences IFN-mediated gene expression in macrophages:</p><p>1. Lines 204-205: The authors find that sgRNAs targeting other complexes of the ETC, including CIII and CIV, had no effect on the ability of IFNγ to stimulate expression of cell surface markers. How do the authors interpret these findings, since CI does not work in isolation in the ETC and is rather dependent on CIII and CIV activity?</p><p>2. How does IFNγ stimulation affect ETC activity, for example as assessed by Seahorse?</p><p>3. Figure 6D: Not clear whether similar exposures were used in different panels. Would be better to load samples in the same gel so that the same exposure can be used and a direct comparison between conditions can be made.</p><p>4. Figure 6D: Does acute treatment with rotenone have similar effects in reducing JAK-STAT signaling as knockdown of CI subunits? If not, then stable, long-term knockdown of CI subunits may have some effect independent of respiration in influencing JAK-STAT signaling (for example, on expression of some component of the JAK-STAT pathway). This interpretation could also explain why knockdown of other components of the ETC do not have similar effects to CI. Rotenone treatment could be tried and if the data are different from knockdown of CI subunits, then related data in the study could be re-interpreted and conclusions modified.</p><p>5. The authors propose that &quot;CI-dependent regeneration of NAD is the most likely regulator of IFNγ signaling&quot;. This conclusion is based on their observations that oligomycin but not CCCP has a similar effect to rotenone, but many other interpretations are possible. To suggest NAD regeneration as being causal seems a bit of stretch unless some supporting data is provided. For example, does addition of NAD precursors (e.g., NAM) rescue the defects in the CI subunit knockdown?</p><p>Other concerns:</p><p>1. The authors do not mention which macrophages (primary, cell line) they use for their screen.</p><p><italic>Reviewer #2:</italic></p><p>– In figure 1E the authors suggest the importance of TNF receptor in regulating CD40 expression. Did the authors measure TNF production in the supernatant of their cell line treated with IFNγ? Based on the literature and on Figure 5C, there should be no TNF in the culture of IFNγ-treated macrophages. If so, how is it possible that the TNFR is involved? The authors should at least try to block TNF and/or TNFR with blocking antibodies to assess if suboptimal doses of TNF are playing any role.</p><p>– Throughout the paper: the authors often &quot;measure&quot; respiration and/or OXPHOS via measuring ATP levels (eg. Figure 3B and many others). The paper would highly benefit from the use of a seahorse to determine how the treatments made throughout the manuscript affect oxygen consumption and/or the extracellular acidification rate. Using ad hoc methods, it is possible not only to specifically measure OXPHOS and glycolysis, but also to ask important questions when substrates, such as pyruvate or citrate, are used. Most of the conclusions driven on the relevance of either respiration or OXPHOS, as well as ATP production sources, are very indirect and a seahorse would be required to really prove that the conclusions made are correct.</p><p>– The introduction of the cytokine measurement in figure 4 and 5 is indeed important but quite misleading. No real comparison with the findings published by Ivashkiv's group in Nature Immunology in 2015 is made. This paper looks at the involvement of mTORC1, metabolism and other kinases in the transcriptional and translational regulation driven by IFNγ in macrophages. mTORC1 is a key regulator of glycolysis, and IFNγ is shown to inhibit mTORC1, if so, one would expect respiration and/or other metabolic changes may occur and may be somewhat linked to complex I. Also, the fact that in the absence/block of complex I, cytokines in cells treated with TLR2 agonists are boosted is very confounding, and it makes hard to interpret data when complex I is blocked and IFNγ is also administered together with TLR2 stimulation. The authors should either better explain these phenotypes, or only focus on signals that do not involve TLR2 stimulation, leaving these data for a future work.</p><p>– In Figure 3H a key control is missing. What about survival of the cells when the import of the only energy substrate is blocked?</p><p>– The experiment with CCCP suggests that Complex I may regulate macrophage functions independently of OXPHOS. This is maybe the most exciting point of the paper, and it is partially addressed in figure 6D where phosphorylation of JAKs and STATs is analyzed. How do we go from Complex I to the most proximal signaling components of the IFNGR?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.65109.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Lines 204-205: The authors find that sgRNAs targeting other complexes of the ETC, including CIII and CIV, had no effect on the ability of IFNγ to stimulate expression of cell surface markers. How do the authors interpret these findings, since CI does not work in isolation in the ETC and is rather dependent on CIII and CIV activity?</p></disp-quote><p>This is a very interesting question, and we agree that it was not addressed directly enough in the original manuscript. Based on the data in the manuscript, it remained possible that CIII and CIV were not identified in the screen due to a technical issue, such as gene essentiality. Alternatively, these data could suggest that CI is still able to support IFNγ signaling in the absence of these downstream complexes, perhaps by transferring electrons to an alternative acceptor. In the revised manuscript, we test this directly using small molecule inhibition of CIII and CIV using antimycin A and sodium azide respectively. While treatment with either inhibitor reduced ATP to a similar degree as rotenone, the effect on IFNγ-mediated MHCII expression was significantly less. These results are very similar to what we observed with oligomycin which reduced the IFNγ responses but not to the same magnitude as complex I inhibition. Both the data from our screen and these more direct inhibition data support a preferential role complex I in the IFNγ response. While a detailed investigation electron flux and alternative acceptors is clearly outside the scope of this manuscript, we dedicate a new section in the discussion to this topic.</p><disp-quote content-type="editor-comment"><p>2. How does IFNγ stimulation affect oxidative metabolism as assessed by Seahorse? In order to corroborate the authors' conclusions regarding activity of individual ETC complexes (point 1 above), Seahorse analysis of individual complexes is also advised.</p></disp-quote><p>As suggested, we have performed Seahorse analysis on IFNγ- treated macrophages. The new Figure 2F shows that IFNγ increases basal ECAR and OCR of macrophages. This panel also incorporates inhibitors of individual complexes, showing that both basal and maximal OCR are increased following IFNγ. These data are now discussed in lines 233-241.</p><disp-quote content-type="editor-comment"><p>3. The authors do some limited analyses in human MDMs to suggest that their findings in the mouse macrophage cell line can be generalized to other macrophage populations. It would be great if the analyses in the human MDMs could be extended to further strengthen the generality of their central findings.</p></disp-quote><p>This was an excellent suggestion. In the new Supplemental Figure 2, we now provide the requested data from monocytes and M-CSF derived macrophages, which are consistent with the GM-CSF-derived MDM studies in the original manuscript (current Figure 5). Thus, the role for OXPHOS in IFNγ responses are common to a variety of human monocyte/macrophage cell types.</p><disp-quote content-type="editor-comment"><p>4. Figure 6D: Not clear whether similar exposures were used in different panels. Would be better to load samples in the same gel so that the same exposure can be used and a direct comparison between conditions can be made.</p></disp-quote><p>This entire experiment was redone. In addition to loading all samples on the same gel, we have included a rotenone treatment, as suggested in Point 5. These studies unequivocally show that chemical or genetic inhibition of complex I reduces IFNγ receptor signaling.</p><disp-quote content-type="editor-comment"><p>5. Figure 6D: Does acute treatment with rotenone (but not inhibitors of other ETC complexes) have similar effects in reducing JAK-STAT signaling as knockdown of CI subunits? If not, then stable, long-term knockdown of CI subunits may have some effect independent of respiration in influencing JAK-STAT signaling (for example, on expression of some component of the JAK-STAT pathway). This interpretation could also explain why knockdown of other components of the ETC do not have similar effects to CI. Rotenone treatment could be tried (and compared with inhibitors of other ETC complexes), and if the data are different from knockdown of CI subunits, then related data in the study could be re-interpreted and conclusions modified.</p></disp-quote><p>This was a very insightful comment. As discussed above, this suggested experiment was performed and we found that short-term rotenone treatment reduces Stat1 and Jak2 phosphorylation to a similar degree as genetic inactivation of this complex (Figure 6D). This experiment strengthens our conclusion that complex I activity is necessary for the IFNγ response.</p><disp-quote content-type="editor-comment"><p>6. In Figure 3H a key control is missing. What about survival of the cells when the import of the only energy substrate is blocked?</p></disp-quote><p>This comment helped us realize that these data were presented in a confusing manner. The reviewer is asking if blockade of pyruvate transport results in increased cell death when pyruvate is the sole carbon source. We now realize that including this piece of data is needlessly confusing. The purpose of this experiment is to show that the IFNγ response is intact when the glucose in the medium was replaced with pyruvate or citrate, and therefore that OXPHOS is sufficient to activate IFNγ responses. We used the inhibitor of pyruvate transport simply to show that the commercially-purchased basal media was properly formulated and the cells were dependent on the added pyruvate. These data are clearly not essential for the conclusions drawn, and their inclusion produced confusion. Thus, to ensure clarity we removed the data using the inhibitor which will not impact any conclusions.</p><disp-quote content-type="editor-comment"><p>7. The authors could consider placing their findings in the context of the broader literature. (As just one example, Ivashkiv Nat Imm 2015 described a role for mTORC1 and metabolism in IFNγ-mediated transcriptional and translational regulation in macrophages.) This would increase the impact of their findings.</p></disp-quote><p>As suggested, we have expanded our discussion of mTORC1 and IFNγ-mediated responses in the context of the Ivanshkiv 2015 manuscript to place our work in the broader context of IFNγ signaling regulation. This additional discussion and citations can be found in the introduction and discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>In this manuscript, Olive and colleagues used a genetic screen to identify mitochondrial Complex I as a regulator of IFNγ-mediated gene expression in macrophages. They attribute this role of CI to effects on the activity of the JAK-STAT pathway downstream of the IFNγ receptor. They show that T cell stimulatory activity is a consequence of CI activity.</p><p>There are some questions regarding the authors' proposed mechanism for how CI activity influences IFN-mediated gene expression in macrophages:</p><p>1. Lines 204-205: The authors find that sgRNAs targeting other complexes of the ETC, including CIII and CIV, had no effect on the ability of IFNγ to stimulate expression of cell surface markers. How do the authors interpret these findings, since CI does not work in isolation in the ETC and is rather dependent on CIII and CIV activity?</p></disp-quote><p>This is addressed in Point #1 of the essential revisions section.</p><disp-quote content-type="editor-comment"><p>2. How does IFNγ stimulation affect ETC activity, for example as assessed by Seahorse?</p></disp-quote><p>This is addressed in Point #2 of the essential revisions section.</p><disp-quote content-type="editor-comment"><p>3. Figure 6D: Not clear whether similar exposures were used in different panels. Would be better to load samples in the same gel so that the same exposure can be used and a direct comparison between conditions can be made.</p></disp-quote><p>This is addressed in Point #4 of the essential revisions section.</p><disp-quote content-type="editor-comment"><p>4. Figure 6D: Does acute treatment with rotenone have similar effects in reducing JAK-STAT signaling as knockdown of CI subunits? If not, then stable, long-term knockdown of CI subunits may have some effect independent of respiration in influencing JAK-STAT signaling (for example, on expression of some component of the JAK-STAT pathway). This interpretation could also explain why knockdown of other components of the ETC do not have similar effects to CI. Rotenone treatment could be tried and if the data are different from knockdown of CI subunits, then related data in the study could be re-interpreted and conclusions modified.</p></disp-quote><p>This is addressed in Point #5 of the essential revisions section.</p><disp-quote content-type="editor-comment"><p>5. The authors propose that &quot;CI-dependent regeneration of NAD is the most likely regulator of IFNγ signaling&quot;. This conclusion is based on their observations that oligomycin but not CCCP has a similar effect to rotenone, but many other interpretations are possible. To suggest NAD regeneration as being causal seems a bit of stretch unless some supporting data is provided. For example, does addition of NAD precursors (e.g., NAM) rescue the defects in the CI subunit knockdown?</p></disp-quote><p>We agree that the mechanism linking CI and IFNg signaling remains unclear. The reasoning that lead us to favor NAD+ regeneration is laid out in a very circumspect manner and restricted to the discussion section. After re-reading this text, we do not feel that our result are over-interpreted. Instead, we used the discussion section to revisit the data and speculate on possible mechanisms. Upon reviewing this text we hope the reviewer will agree that this is an appropriate use of the discussion section.</p><disp-quote content-type="editor-comment"><p>Other concerns:</p><p>1. The authors do not mention which macrophages (primary, cell line) they use for their screen.</p></disp-quote><p>This has been clarified in the main text.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>– In figure 1E the authors suggest the importance of TNF receptor in regulating CD40 expression. Did the authors measure TNF production in the supernatant of their cell line treated with IFNγ? Based on the literature and on Figure 5C, there should be no TNF in the culture of IFNγ-treated macrophages. If so, how is it possible that the TNFR is involved? The authors should at least try to block TNF and/or TNFR with blocking antibodies to assess if suboptimal doses of TNF are playing any role.</p></disp-quote><p>While this issue is somewhat tangential to the major conclusions of the study and this comment was not listed as an “essential revision”, we agree that it is important to clearly state the limitations of our work. To be clear and transparent, the revised manuscript now states, “While these results do not define the full TNF-related signaling pathway, they are consistent with the specific association between TNF receptor expression and CD40 induction.”</p><disp-quote content-type="editor-comment"><p>– Throughout the paper: the authors often &quot;measure&quot; respiration and/or OXPHOS via measuring ATP levels (eg. Figure 3B and many others). The paper would highly benefit from the use of a seahorse to determine how the treatments made throughout the manuscript affect oxygen consumption and/or the extracellular acidification rate. Using ad hoc methods, it is possible not only to specifically measure OXPHOS and glycolysis, but also to ask important questions when substrates, such as pyruvate or citrate, are used. Most of the conclusions driven on the relevance of either respiration or OXPHOS, as well as ATP production sources, are very indirect and a seahorse would be required to really prove that the conclusions made are correct.</p></disp-quote><p>This is addressed in Point #2 of the essential revisions section. In the revised manuscript, we characterize the effects of IFNγ treatment by Seahorse, and only rely on ATP measurements to verify expected the metabolic deficiencies of engineered cell lines. We hope the reviewer agrees that the manuscript is improved and our conclusions are adequately supported.</p><disp-quote content-type="editor-comment"><p>– The introduction of the cytokine measurement in figure 4 and 5 is indeed important but quite misleading. No real comparison with the findings published by Ivashkiv's group in Nature Immunology in 2015 is made. This paper looks at the involvement of mTORC1, metabolism and other kinases in the transcriptional and translational regulation driven by IFNγ in macrophages. mTORC1 is a key regulator of glycolysis, and IFNγ is shown to inhibit mTORC1, if so, one would expect respiration and/or other metabolic changes may occur and may be somewhat linked to complex I. Also, the fact that in the absence/block of complex I, cytokines in cells treated with TLR2 agonists are boosted is very confounding, and it makes hard to interpret data when complex I is blocked and IFNγ is also administered together with TLR2 stimulation. The authors should either better explain these phenotypes, or only focus on signals that do not involve TLR2 stimulation, leaving these data for a future work.</p></disp-quote><p>This comment refers to the human macrophage studies in Figure 5B-C. We agree that these data are not mechanistically enlightening. However, in the larger context of macrophage function, we expect that readers will be interested in the effect of OXPHOS on cytokine production during combined stimulation with IFNγ and Pam3CSK4. If the reviewer finds the inclusion of these data counterproductive, we will gladly omit them. However, we prefer to include these observations, as they will answer an obvious question in many readers minds.</p><disp-quote content-type="editor-comment"><p>– In Figure 3H a key control is missing. What about survival of the cells when the import of the only energy substrate is blocked?</p></disp-quote><p>This is addressed in Point #6 of the essential revisions section.</p><disp-quote content-type="editor-comment"><p>– The experiment with CCCP suggests that Complex I may regulate macrophage functions independently of OXPHOS. This is maybe the most exciting point of the paper, and it is partially addressed in figure 6D where phosphorylation of JAKs and STATs is analyzed. How do we go from Complex I to the most proximal signaling components of the IFNGR?</p></disp-quote><p>That’s a great question. Our thoughts on this mechanism are outlined in the discussion.</p></body></sub-article></article>